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Islet transplantation as a treatment for type-1 diabetes in humans has reached a plateau, 
and major breakthroughs in stem-cell based therapies and immunoprotection strategies 
are now needed to advance the field. The primary goal within this dissertation was to 
approach innovation in islet transplantation from a new perspective: veterinary medicine 
and canine diabetes. Canine diabetes, while strikingly similar to type-1 diabetes in 
humans, has been entirely overlooked as a market for islet transplantation, and is in 
significant need of better treatment options. The obvious clinical need and regulatory 
advantage in veterinary medicine creates an attractive environment to cultivate much 
needed innovation in the field of islet transplantation. This overall goal was addressed 
with the following specific aims:  
 
1] develop and optimize practical, ethical, and cost effective methods for obtaining 
transplant quality islets from canine donors  
2] demonstrate and evaluate long-term efficacy of an alternative (non-alginate) hydrogel 
for immunoprotected islet transplantation in an allogeneic diabetic rat model 
3] develop a non-toxic, simple, and readily translatable method for fabricating hydrogel 
(non-alginate) microspheres for cell encapsulation and delivery 
 
In accomplishing these aims, significant groundwork for islet transplantation as a 
treatment option for diabetic canines has been laid. A major focus of this research was in 




acid (HA) based hydrogel as an alternative to standard alginate microspheres. Islets 
transplanted within the HA gel reversed diabetes in immune competent allogeneic rats 
for a minimum of 10 months. In light of these results, I developed, characterized, and 
patented a novel method for producing islet-laden HA hydrogel microspheres designed 
for use with readily available materials and cGMP complaint equipment. Furthermore, this 
novel method has great potential as a platform technology for generating cell-laden 
hydrogel microspheres using a variety of biomaterials for broad application in 
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CHAPTER 1: Introduction to Dissertation 
 
The promise of islet transplantation as a cure for type-1 diabetes is as exciting as it is 
evasive. Despite decades of research, the procedure still resides in the experimental 
realm, used only as a last resort when standard treatments fail. This dissertation, through 
a unique industry collaboration, was shaped by a fresh approach to the commercial 
translation of islet transplantation: bring it to pets, not people. Through this approach 
came practical advancements applicable not only to canine islet transplantation 
specifically, but to the field in general, as commercial success in the veterinary space 
could serve as a blueprint for human translation. Further, in addressing this goal I 
developed a novel and versatile cell encapsulation platform based on hydrogel 
microspheres with broad potential value in tissue engineering and regenerative medicine, 
resulting in an issued United States Patent.  
 
Islet transplantation in humans has been stifled for the following basic reason: the costs, 
both financial and punitive, far outweigh the benefits for the vast majority of patients. 
Recipients of islet transplants must take harmful anti-rejection drugs, and donor islets are 
scarce and expensive to procure. Alternatively, most type-1 diabetics can effectively 
manage their diabetes via insulin therapy, and therefore cannot justify an islet transplant. 
The same is not true for diabetic canines, which are of course unable to care for 
themselves. Instead, their human counterparts must administer twice daily insulin 
injections and closely regulate their diet. Despite these efforts, many diabetic dogs 




veterinary community is in dire need of a better way to address the growing problem of 
diabetes in pets.  
 
An important advantage to the veterinary pathway is a more hospitable regulatory 
environment, enabling the much-needed innovation in this field to move more efficiently 
into the clinic. However, the cost and complexity of current methods for obtaining quality 
islets are too extreme to be viable in veterinary medicine; improvement in the area of 
canine islet isolation will be vital to achieving this overall goal. Beyond this, there is a 
major need for progress – for both human and veterinary application - in the prevention 
of transplant rejection through islet encapsulation. Current encapsulation strategies are 
dependent on sodium alginate hydrogel spheres, which have long suffered from poor 
biocompatibility and consistent failure outside of the laboratory. This dissertation sought 
to address these needs through the following specific aims:  
 
1] develop and optimize practical, ethical, and cost effective methods for obtaining 
transplant quality islets from canine donors  
2] demonstrate and evaluate long-term efficacy of an alternative (non-alginate) hydrogel 
for immunoprotected islet transplantation in an allogeneic diabetic rat model 
3] develop a non-toxic, simple, and readily translatable method for fabricating hydrogel 
(non-alginate) microspheres for cell encapsulation and delivery 
 
Chapter 2 of this dissertation contains supportive background material and describes the 




under the purview of human diabetes, and the challenges facing the field today. Next, I 
discuss the historical role of canines in islet transplantation, and establish a basis for the 
veterinary application of this treatment. The chapter concludes by re-examining some of 
the challenges to islet transplantation in the context of canines and veterinary medicine, 
thus providing motivation for the research presented in the subsequent chapters.  
 
Chapter 3 addresses my first aim by confronting the challenges to islet isolation that are 
unique to veterinary medicine and the canine anatomy. Specifically, it describes a 
simplified method for isolating canine islets, optimized to account for the marked size 
variability of canine pancreas and the deleterious conditions surrounding deceased 
donor-based organ procurement (i.e. as opposed to heart-beating pancreas retrieval 
standard in human practice).  
 
Chapter 4 addresses the second aim to identify and evaluate an alternative material to 
the standard sodium alginate gels as an islet encapsulant. In these studies, we examined 
a hyaluronic acid (HA) based hydrogel system for potential use as an immunoprotective 
biomaterial for islet transplantation. The HA gel was characterized in vitro to elucidate 
material-derived effects on encapsulated islet viability, morphology, survival, and function 
over 28 days. These studies included a direct comparison to both alginate-encapsulated 
islets and un-encapsulated controls. The gel was then examined in vivo using an 
allogeneic diabetic rat model to monitor long-term efficacy and biocompatibility of islets 




recipients for a minimum of 10 months and showed no signs of a negative host response 
to the biomaterial.  
 
Chapter 5 addresses the third and final aim to develop a method for fabricating islet-
microspheres from alternative hydrogel materials (i.e. not alginate). Microspheres are 
highly preferred for simple delivery and improved diffusion characteristics compared to 
macroscopic hydrogel constructs. However, current techniques for fabricating islet-
hydrogel microspheres are highly limited, with sodium alginate by far the most common 
material due to its unique, near instantaneous gelation kinetics. Here, I introduce a novel 
method for producing islet/cell-laden microspheres compatible with a variety of hydrogel 
systems, including photo-initiated and chemically cross-linked hydrogels. The method 
was developed with standard, fully sterile, cGMP-compliant droplet generation 
instrumentation and readily available materials to facilitate smooth commercial 
translation, regulatory compliance, and scale, and was awarded a United States Patent. 
 
Chapter 6 concludes with a concise summary of the experimental chapters and a 
discussion of potential applications and opportunities for future development. 
Supplemental data and commentary related to the primary dissertation work, including 
studies performed toward the development of the novel microencapsulation method, are 





CHAPTER 2: Background 
 
Introduction to Human Islet Transplantation 
Nearly two decades ago, seven type-1 diabetic patients were effectively cured by a simple 
intravenous injection of pancreatic islets. 1 This landmark study, now known as the 
Edmonton Protocol 1, gave hope of a normal lifestyle to type-1 diabetics, which total about 
1.25 million in the United States alone. 2,3 Transplant success rates and duration have 
continued to improve since these initial reports 3–5, yet the number of patients treated 
annually has essentially not changed in ten years according to the most recently available 
data from the Collaborative Islet Transplant Registry (CITR) 2, shown in figure 2.1. This 
is even more disheartening considering the rising prevalence of type-1 diabetes, which is 
increasing by 3% per year, globally. 6 The following sections explore the two fundamental 
challenges responsible for the unfortunate obstruction of an otherwise promising 
treatment: donor islet supply and graft rejection. 
 
Human Donor Islet Supply and Islet Isolation 
Islet transplants, like a heart or lung transplant, require organs from deceased donors. 
However, unlike heart or lung transplants, islets from multiple donors are typically 
required to restore insulin independence in a single recipient. For example, 2,146 donated 
pancreas were used to treat a total of 864 patients in North America from 1999-2012, an 
average of 2.48 donors per recipient. 7 In theory, one donor pancreas does contain a 
sufficient quantity of islets to properly regulate blood glucose in a typical recipient. 




thus been a major focus of type-1 diabetes research for decades.     
 
Essentially all current islet isolation protocols used for clinical islet transplantation are 
based on a method described by Ricordi et al. in 1988. 8 Donor pancreas are first 
preserved during procurement by vascular flushing with an organ preservation solution 
and transported on ice to a processing facility. The pancreas is then perfused with a 
solution of digestive enzymes through the pancreatic ductal system, warmed, and then 
digested with the aid of an automated mechanical agitation device. During digestion, islets 
are liberated from their collagenous matrix in the pancreatic tissue. The pancreatic digest 
is then further processed to separate the islets, which account for only 1-2% of the 
pancreas, from the other pancreatic tissue, called exocrine or acinar tissue. 9 This is 
achieved by density gradient centrifugation, exploiting the lower native density of islets 
relative to the exocrine tissue. Briefly, the pancreatic digest is deposited into a vessel 
containing layers of fluid of variable density, typically Ficoll, and then centrifuged. Islets 
travel to lower density regions and can be collected separately from the heavier exocrine 
tissue. In practice, islets are rarely obtained at 100% purity, as exocrine tissue is highly 
susceptible to environmental stress and often swells with water, reducing its density to 
within the range of islets. Numerous strategies have been developed to help alleviate this 
issue, and are covered in greater detail in later in this dissertation. 10–15  
 
The method reported by Ricordi in 1988 yielded 164,600 islets per pancreas (an average 
of 2279 islets/gram of pancreas) with an islet purity of 78.5%. 8 By comparison, a multi-




of 353,900 islets per pancreas, demonstrating the clear progress made in the field. 16 
However, this number is still well short of the roughly 1 million islets generally estimated 
to reside in the average human pancreas. Furthermore, because islets, which are 
aggregates of hundreds to thousands of cells, range in size from approximately 50-400 
microns in diameter, simply counting the number of islets quickly proved to be a poor 
measure of actual islet cells present. 17–22 Thus, the method for conversion to “islet 
equivalents”, or IEQ, was developed and published, again by Ricordi et al., which defined 
an islet equivalent as the number of islet cells contained in one islet of 150 microns in 
diameter. 23 Islet preparations are converted to IEQ through a process of binning islets by 
size range and then multiplying by a standard conversion factor. As an example, the islet 
number of 353,900 mentioned above converted to 244,400 IEQ, indicating that a majority 
of the islets were below 150 microns in diameter. 16  
 
Islet isolation protocols have continued to improve, particularly in the wake of the inspiring 
clinical results of the Edmonton Protocol in 2000. Barbaro et al. reported an even higher 
average yield of 368,419 IEQ/pancreas from 132 isolations performed between 2004 and 
2006 using a custom density gradient. Experimental islet isolation protocols (i.e. not 
implemented for clinical transplantation) report islet yields that are better still. Noguchi et 
al. described an isolation method utilizing yet another custom density gradient that 
returned 594,136 IEQ per human pancreas (N=11) in a 2009 publication.  
 
While advancements in islet isolation have been of great value toward the ongoing pursuit 




ultimately governed by the number of qualified donor pancreas. That number, 
unfortunately, is only a small fraction of what is needed. The United States Organ 
Procurement and Transplantation Network reported a national average of 1,475 pancreas 
donations per year from 1988 through 2016, the majority of which were transplanted as 
whole organs. 24–26 Meanwhile, an estimated 40,000 new cases of type-1 diabetes are 
diagnosed every year to add to the 1.25 million patients currently diagnosed in the United 
States. 2,3,6 With an average of 2.48 donor pancreas required per recipient, it is abundantly 
clear that the current donor-based approach can never reach the overwhelming majority 
of diabetic patients. This reality, however, was understood and accepted long ago by the 
islet transplantation community. Consequently, extensive research has been underway 
for decades in search of an alternative and scalable replacement for donor-derived islets, 
namely, through stem cell-based approaches.  
 
Islet Graft Rejection and Immunoprotection in Humans 
While donor supply is clearly a current challenge for clinical islet transplants, the second 
area of need is in the prevention graft rejection.  Islet transplants, though far less invasive 
than a traditional organ transplant, are just as vulnerable to rejection by the host’s immune 
system. In fact, a major factor in the success of the Edmonton Protocol was the 
immunosuppressive regime administered in conjunction with the islet infusions. Patients 
were given a cocktail of sirolimus, tracrolimus, and daclizumab, notably free of the 
traditional glucocorticoid based immunosuppressants that were known to cause islet cell 
damage and peripheral insulin resistance. 1,27,28 This approach led to vastly improved 




islet allografts performed between 1990 and 1999, only 12.4 percent resulted in insulin 
independence for more than a week. 28 By comparison, all seven of the original Edmonton 
patients were insulin independent for a minimum of four months, with an average duration 
of one year. 28  
 
Further improvements in immunosuppression and transplantation protocols have led to 
reduced initial failure rates and prolonging graft lifetime. In the early phases after the 
Edmonton study, insulin independence rates were 10% after five years. As such, the 
significantly more invasive but more efficacious whole pancreas transplant was still the 
preferred option for patients able to withstand the surgical trauma. 29 Recent five-year 
insulin independence rates were 50% at high quality islet transplant centers and 40% for 
single donor transplants, 5,30–34 approaching outcomes of whole pancreas transplantation, 
which are between 60-80% graft survival at 5 years. 35,36 Thus, islet transplantation has 
gained significant ground as a less invasive alternative to pancreas transplant even in 
patients healthy enough to undergo an open abdominal surgery. 
 
Immunosuppressive therapy after islet transplantation must be continued for the lifetime 
of the graft to prevent rejection, though rejection eventually occurs regardless in many 
cases. Along with these medications come side effects including nephrotoxicity, mouth 
ulcers, peripheral edema, hypertension, and increased infection risk. 37,38 Meanwhile 
exogenous insulin therapy continues to improve, and most type-1 diabetics can effectively 
self-manage their blood glucose levels to a point that immunosuppression would result in 




and uncontrollable glycemic dysfunction, or to those that are already on 
immunosuppressive therapy for another transplant, most often a kidney. 3,5,39,40  
 
The glaring limitations of immunosuppression gave rise to another approach to islet 
transplantation called immunoprotection, otherwise known as cell encapsulation. The 
concept of immunoprotection is not to suppress the host immune system, but rather to 
hide from it. To accomplish this, cells are encapsulated within a semi-permeable, micro-
porous polymer network, for example a hydrogel, that allows free exchange of nutrients 
and signaling molecules (e.g. insulin) while preventing host immune cells from contacting 
transplanted cells.  41–45  A graphical representation of this concept is provided in figure 
2.2 for additional clarity. This clever strategy is enabled by the tremendous size difference 
between cells and biomolecules. A typical T-cell is about 8 microns in diameter, while the 
hydrodynamic radius of albumin, a common biological protein, is only 3.5 nanometers, 
more than 1000 times smaller. 46 Through this approach, transplanted islets can be 
shielded from rejection without the use of harmful immunosuppressive drugs.  
 
By far the most common material used for immunoprotection is calcium alginate, with the 
first successful allogeneic transplants reported by Lim and Sun in 1980 (in rodents). 47 
Alginate is a seaweed derived polymer that, when combined with a free divalent cation, 
usually calcium, instantaneously cross-links into a rigid hydrogel network. Calcium-
alginate gelation occurs so rapidly that droplets of liquid alginate solution dispensed into 
a bath containing calcium harden immediately into small, spherical, hydrogel microbeads 




minimal cytotoxicity are the basis for the widespread popularity of this material for islet 
transplantation. Notably, the transplants performed by Lim and Sun lasted for only a few 
weeks, and many issues with encapsulated transplantation still remain, but more than 
sufficient progress has been made in this area to justify continued research. 
 
Though significant progress has been achieved through sophisticated alginate 
purification techniques and improved microsphere geometry 48–53, long-term results have 
disappointed due to biocompatibility issues with this material. 54–59 In response, 
researchers have begun to explore new, advanced biomaterials and devices for islet 
transplantation and cell encapsulation in general. Much of the alginate-free technology 
has come in the form of macroscopic implantable devices. A recent macro-device, called 
the Beta-Air, consists of a small chamber containing islets surrounded by a semi-
permeable synthetic mesh that allows for nutrient exchange. The device is surgically 
implanted beneath the skin and injected daily with oxygen through a transdermal port to 
improve islet survival. 60 Showing promise in rodents and pigs, a company was formed 
around the technology and began a phase I/II clinical trial (ID: NCT02064309) in humans 
in 2014 that is currently active. Another approach, known as conformal coating, utilizes 
advanced techniques to coat individual islets in an ultrathin polymer membrane in an 
effort to reduce transplant volume compared to traditional hydrogel microspheres. A 
company by the name Novocell showed promising results in baboons with a polyethylene 
glycol (PEG) based conformal coating, but could not replicate their results in a phase I 





Immunoprotection has the potential to truly transform the field of islet transplantation. 
Eliminating the need for immunosuppression, and thereby numerous side effects, would 
dramatically expand the population of patients for which an islet transplant would be 
justifiable. Furthermore, viable immunoprotective technologies will be an integral 
component in the safe delivery of other cell-based therapies, including stem cells, as they 
become available.  
 
Canines Diabetes and Islet Transplantation 
Canines are known to spontaneously contract a form of diabetes that closely resembles 
type-1 diabetes in humans. It is perhaps for this reason that canines and islet 
transplantation have a very long history together. After the first reported attempt at a 
human islet transplant, published in 1977 61, failed to reverse diabetes, the use of canine 
research models became increasingly common as investigators strived to better 
understand the procedure. 23,62–68 In fact, much of the progress in pancreas preservation, 
islet isolation, immunosuppression, and transplant surgery can be attributed to canine 
research throughout the evolution of islet transplantation. Multiple studies reported 
achieving insulin independence in dogs for several months and up to 600 days in some 
cases. 67,69–71 Of note, these studies were done using research animals with induced, not 
spontaneous, diabetes. However, Alejandro et al. reported insulin independence in 3 of 
8 spontaneously diabetic dogs for 253-716 days. Interestingly, this study was published 
in 1988, long before the era of advanced immunosuppression agents that arrived with the 





Considering the historical success in canine islet transplantation research, the absence 
of this treatment from veterinary medicine seems like an obvious oversight. Approximately 
1 in 400 dogs in the United States is diagnosed with diabetes and incidence rates are 
steadily climbing, yet treatment options for diabetic pets have stagnated while human 
diabetes care is improving rapidly. 73,74 The standard treatment for canine diabetes is 
twice daily insulin injections administered, of course, by a human counterpart. Glycemic 
control with this method is often very poor despite the best efforts by the pet’s owner to 
control diet and monitor symptoms. As a result, these animals commonly experience 
diabetic complications including infection, loss of vision, and ketoacidosis. 75 Sadly, when 
faced with the reality of caring for a diabetic pet, euthanasia is an all too frequent 
alternative. These factors combined build a compelling case to re-examine islet 
transplantation in canines, but now as patients, not subjects. 
 
The idea of islet transplantation in veterinary medicine presents an intriguing and 
potentially synergistic opportunity. The high prevalence of canine diabetes in conjunction 
with a poor standard of care has created extraordinary need in the veterinary community 
for improvement. Further, veterinary medicine is a more receptive environment for 
innovation both from a regulatory and financial risk perspective. To this point, a review by 
Scharp et al. describes 22 separate corporate attempts to translate human islet 
transplantation technologies that started and failed between 1980 and 2010. 76 Ironically, 
many of these companies showed initial promise in large animals, including canines, but 
were ultimately unsuccessful in humans. Alternatively, technologies developed for 




importantly, be exempt from the tremendous capital risk associated with moving from 
animal studies to human clinical trials. Moreover, successes achieved in canines could 
serve as a blueprint, even as preclinical data, for human applications in the future. 
 
Canine Islet Isolation for Veterinary Medicine 
A necessary element for bringing islet transplantation to canines is, of course, canine islet 
tissue, and there are several important points to consider in this regard. First and foremost 
is the fact that the vast majority of canine islet transplantation research utilized islets 
obtained from purpose-bred laboratory animals. While justifiable in experimental 
research, this would be profoundly unethical in clinical practice. Rather, tissues for canine 
islet transplants must be obtained, as with human transplants, through organ donation. 
This introduces another point of consideration: pancreas procurement conditions. Human 
pancreas are procured by a team of specially trained medical personnel, typically from a 
beating-heart donor, and preserved through a complex vascular flushing process. 16,77,78 
In contrast, canine pancreas will most likely be obtained from deceased donors that were 
euthanized for other reasons at local veterinary clinics or animal shelters. Further, these 
canine organs will be exposed to increased periods of warm and cold ischemia relative 
to human organs, and complex vascular flushing procedures are not feasible in veterinary 
settings. Unfortunately, these harsh conditions can lead to extensive tissue damage and 
significantly diminish islet yield and quality. 79–82 Thus, new islet isolation strategies 
designed specifically for canine pancreas procured in sub-optimal conditions are needed.  
 




pancreas itself. The mass of a typical human pancreas is about 100 grams, with relatively 
small deviation amongst individuals. 16 The mass of a canine pancreas, which is strongly 
correlated to the mass of the animal, varies tremendously. In just our own laboratory, we 
have processed canine pancreas from as small as ten grams and to as large as 120 
grams. Human islet isolation protocols are not designed to account for this level of 
variability, employing large, expensive equipment such as the COBE 2991 cell processor 
and the Ricordi automated digestion system, which require high volumes of costly 
materials for each individual pancreas. 8,83–86 Processing a 10-gram pancreas using these 
protocols would be a wildly inefficient endeavor in the already cost-conscious veterinary 
world. Rather, canine isolation protocols must be designed to accommodate the size 
variability of the canine pancreas, and with minimal use of costly, specialized materials 
and equipment.  
 
Future Development in Immunoprotection 
Immunoprotection strategies will be just as critical to the success of islet transplantation 
in pets as they are for human applications, and for essentially the same reasons. Freedom 
from insulin injections is often not worth the costs associated with a lifetime of 
immunosuppression, particularly when those costs are the direct responsibility of the pet’s 
owner. Thus, an economically feasible veterinary islet transplantation protocol must also 
include an effective immunoprotection strategy. To this point, innovation in this area could 
be expedited in the less rigorous veterinary space, as entry into the target species can be 





Recently, advanced hydrogel materials derived from native and bioinspired materials 
have gained attention in cell encapsulation research due to excellent biocompatibility and 
bioactive characteristics. Examples of these materials include chitosan, a polymer derived 
from the shells of insects and crustaceans, synthetic self-assembling peptide gels, and 
gels conjugated to signaling proteins such as VEG-F. 87–89 Of particular note are hydrogels 
based on hyaluronic acid (HA), which is a primary component of native extracellular 
matrix. Hyaluronic acid gels have become increasingly popular due to their excellent 
mechanical properties and outstanding biocompatibility. 90–95 However, a key drawback 
to these advanced hydrogels is how they are fabricated. Unlike alginate, which forms a 
gel instantaneously, most hydrogels typically require several minutes to solidify. 
Therefore, the simple process for producing small, conveniently injectable microspheres 
that works with alginate does not apply to HA gels. Some methods for producing non-
alginate-based hydrogels do exist, but are based on oil-emulsion techniques and are 
therefore not an attractive option for encapsulating living cells for transplant, where 
sterility, cytotoxicity, and process control are primary concerns. 96,97  
 
Summary 
The penetration of islet transplantation in humans has plateaued, awaiting major 
breakthroughs in renewable stem-cell-derived islet tissues and immunoprotective delivery 
systems. Meanwhile, treatment options for diabetic pets are outdated and only marginally 
effective despite a high prevalence of the disease, and euthanasia is an unfortunate and 





There is ample precedent of efficacy for canine islet transplantation throughout decades 
of research, yet it remains wholly unavailable diabetic dogs and their owners. While this 
is an obvious clinical need in a sizeable market, translating islet transplantation to canines 
is not without challenges. New protocols for islet isolation must be developed that account 
for the specific physiological and economic variables associated with canines and 
veterinary practice. Finally, while the demand on efficacy is far lower in canines than 
humans due to the substantial treatment gap, improvements in immunoprotection and 
non-donor-based tissue sources are still needed to achieve broad clinical relevance. 
However, the veterinary space is an ideal place to foster innovation in this area, with 
reduced regulatory burden and the benefit of a faster and less costly entry into the target 










Figure 2.1. Number of patients that received islet transplants in the United States from 
1999 to 2012.  
Data shown are adapted from the Collaborative Islet Transplant Registry Eighth Annual Report, 
published December 31st, 2014. 2 After the initial publication of the Edmonton protocol, the 
numbers of islet transplantations sharply increase year over year, reaching its peak in 2002. 
However, as improvements slowed and exogenous insulin therapy began to progress rapidly, 







Figure 2.2. Cartoon depiction of immunoprotection (cell encapsulation) using a 
hydrogel.  
Immunoprotection is enabled by the vast size disparity of cells vs. biomolecules through the 
use of a nano-porous polymer network or membrane, a hydrogel in this example. Pores are 
large enough for nutrients (amino acids, oxygen), signaling molecules (glucose, insulin), and 
cell waste to freely diffuse into and out of the gel, yet comparatively large immune cells are 







CHAPTER 3: Increased Efficiency of Canine Islet Isolation 
from Deceased Donors†  
 
Abstract 
Canine diabetes is a strikingly prevalent and growing disease, and yet the standard 
treatment of a twice-daily insulin injection is both cumbersome to pet owners and only 
moderately effective. Islet transplantation has been performed with repeated success in 
canine research models, but has unfortunately not been made available to companion 
animals. A major barrier to the veterinary application of this treatment is the availability of 
high quality, ethically-obtained islet tissue. Standard protocols for islet isolation, 
developed primarily for human islet transplantation, include beating-heart organ donation, 
vascular perfusion of preservation solutions, specialized equipment. Unfortunately, these 
processes are prohibitively complex and expensive for veterinary use.  Here, we describe 
simplified strategies for isolating quality islets from deceased canine donors without 
vascular preservation and with up to 90 minutes of cold ischemia time. An average of 
1500 islet equivalents per kg of donor bodyweight was obtained with a purity of 70%. 
Islets were 95% viable and responsive to glucose stimulation for a week. Histological 
examination of the canine pancreas further confirmed marked regional disparities in islet 
distribution, with the vast majority of islet cells located in the tail and main body of the 
pancreas. We found that processing only the body and tail of the pancreas dramatically 
increased isolation efficiency without sacrificing islet total yield. Islet yield per gram of 
                                            
† Submitted as Harrington, S., Williams, S., Otte, V., Barchman, S., Jones, C., Ramachandran, 
K., Stehno-Bittel, L. “Increased Efficiency of Canine Islet Isolation from Deceased Donors,” for 




tissue increased from 773 to 1868 islet equivalents when the head of the pancreas was 
discarded. In summary, this study resulted in the development of a repeatable, cost 
efficient, and readily accessible method for obtaining viable and functional canine islets 
from deceased donors. These strategies provide a reliable and ethical means for 
obtaining donor islets, and thus represent an important step toward the potential 





One in every 333 dogs in the United States is currently diagnosed with diabetes mellitus, 
and incidence rates are steadily increasing.  98 Indeed, rates of canine diabetes have more 
than doubled since 2007.  73,98 Apart from an obvious financial sacrifice, caring for a 
diabetic pet requires twice daily insulin injections, frequent veterinary assessments, and 
strict dietary constraints. Despite these extreme measures, glycemic control in diabetic 
canines often remains poor, which leads to major complications such as infections, 
diabetic ketoacidosis, and loss of vision. 75 As such, access to islet transplantation, which 
restores natural glucose regulation and eliminates the need for insulin injections, would 
be an extraordinary step forward in veterinary diabetes care. In humans with brittle 
diabetes, islet transplants have successfully provided normoglycemia since 2000, when 
the Edmonton protocol was introduced. 1 By 2005 approximately 70% of patients were 
insulin independent at 1 year after transplantation 29, and 37% were still insulin 
independent at 3 years. 5 More recent statistics indicate that 44% of diabetics are still 
insulin independent 3 years after their transplant. 4 Canines were used extensively as 
research and preclinical models for human islet transplantation with promising outcomes, 
and yet the veterinary application of this research has never been earnestly pursued. 
64,67,69,70,99–102 Vrabelova et al. recently published an excellent review to this very point, 
demonstrating a promising opportunity to meet an obvious veterinary need. 68  
 
Perhaps the most critical factor for successful application of islet transplantation in 
companion animals will be reducing the cost of, and expanding access to, quality donor 




animals under optimal, controlled conditions, i.e. beating-heart donors, minimal periods 
of ischemia, specialized equipment, and little regard to cost. However, these ideal 
conditions for islet isolation are simply not feasible in veterinary practice. Furthermore, 
the use of purpose-bred dogs for on-site, beating-heart pancreas procurement is both 
costly and regarded as highly unethical. Rather, donor pancreata will likely be obtained 
off-site from already euthanized donors at veterinary clinics through organ donation 
programs, and then transported to a separate facility for processing. Consequently, there 
is a clear need for a simple and cost effective strategy to obtain transplant quality islets 
from euthanized donors where ischemic injury is inevitable. Recently, some promising 
results were reported using euthanized canine donors, but islet yields were relatively low 
and inconsistent. 103 Further, the method utilized a costly Ricordi chamber and complex 
temperature controlled perfusion system. Thus, continued improvements in this space will 
be necessary to make veterinary islet transplantation a reality. 
 
In the present study, we sought to develop a simple, scalable, and cost-effective method 
that could be used to consistently procure large quantities of transplant-quality canine 
islets from euthanized donors using standard laboratory equipment and materials. To 
accomplish this, we first developed a custom cold preservation solution and an advanced 
density gradient medium using readily available components. We also administered 
heparin prior to euthanasia and incorporated a simple ductal purging step to eliminate 
residual blood in lieu of more complex vascular preservation and flushing. Finally, 




the tail region 21,104, we evaluated the implications of omitting the head of the pancreas 
from the isolation process on overall islet yield, purity, viability and function.  
 
Methods 
Organ Preservation Solution 
A modified Histidine-Tryptophan-Ketoglutarate (HTK) organ preservation solution was 
prepared in house with 5% (w/v) polyethylene glycol (PEG), average M.W. 8000, added 
as an oncotic agent to minimize cellular edema. 105–108 The modified HTK-PEG solution 
was sterilized by filtration through a 0.22 μm filter unit, and the pH and density was 
measured. The density of the HTK-PEG preservation solution was measured using a 
Densito 30PX densitometer (Mettler Toledo) approximately 1.022 g/mL at 20 °C. The 




Pancreas digestion was carried out in a custom buffer of Hank’s Balanced Salt Solution 
(HBSS) containing 10 mM HEPES and 3.2 mM calcium chloride, adjusted to pH 7.6-7.8 




A highly purified collagenase/thermolysin blend, Liberase T-Flex, (Roche Custom 




Enzyme solutions were prepared immediately prior to use at 3 Wunsch Units (WU) of 
collagenase and 0.018 mg thermolysin per mL of buffer. Sufficient volume of enzyme 
solution was prepared for each individual pancreas to achieve approximately 10 WU per 
gram of digested tissue.  
 
High Osmolality Iodixanol/HTK Density Gradient Medium 
A custom density gradient medium was prepared by first adding 5 M sodium chloride to 
a concentrated solution of iodixanol (OptiPrep, CosmoBio USA) to a final calculated 
osmolality of 700 mOsm/kg and a density of 1.315 g/mL at 20 °C, as measured with a 
Densito 30PX densitometer (Mettler Toledo). This high osmolality iodixanol stock was 
then mixed with the modified HTK-PEG preservation solution to create solutions of 
various desired densities. 111 The calculated osmolality of the final gradient media was 
approximately 450 mOsm/kg.11,12,14,112 
 
Pancreas Donors  
Pancreata were obtained from canine donors at local veterinary clinics with consent of 
the owners for organ donation.  Animals were already scheduled for euthanasia for other 
reasons and had no known endocrine disorders. Euthanasia was performed by the 
licensed veterinarian overseeing the care of each animal, and the clinical veterinarian 
confirmed death with loss of heart function. Collection of the donor pancreata after death, 
and from animals euthanized for reasons other than tissue procurement, was determined 
to be exempt from IACUC review by the University of Kansas Medical Center. Canine 





Donor pancreata were categorized into four experimental groups: whole pancreas (W), 
tail and body (TB), no heparin/ductal flush (NH), and histological study (IHC). The IHC 
group was not used for pancreas digestion or islet isolation. 
 
Pancreas Procurement and Preservation 
Prior to euthanasia, donors were given heparin sulfate intravenously at 300 units/kg with 
the exception of the NH study group. After cardiac death, the abdominal fur was shaved, 
and the surface sanitized with Povidone-Iodine sponges (Medline Industries, Inc.) and 
rinsed with 70% ethanol. Then, the abdominal cavity was accessed via gross midline 
incision and a small lateral incision near the stomach. The major splenic and 
pancreaticoduodenal vessels leading into the pancreas were ligated and the duodenum 
was double clamped with large hemostats on either side of the pancreas. The major 
vessels were severed above the ligatures to minimize blood contamination as the 
pancreas was removed with the attached duodenal section. The isolated pancreas was 
then immersed in cold HTK-PEG preservation solution and transported to the laboratory 
for processing.  
 
Tissue Processing for Histological Studies  
For histological analysis (donor ICH1, Table 3.1), the pancreas was manually dissected 
into three parts (head, middle and tail).  The tissues were fixed using the general methods 
we have previously described. 113 Samples were placed in 10% normal buffered formalin 




embedded in paraffin using an automated vacuum tissue processor Leica ASP300S 
(Leica Microsystems Inc. Bannockburn, IL) and stored at +4°C. The samples were 
sectioned in 7 µm thicknesses using a microtome RM2255 (Leica Microsystems) and 
mounted directly on Superfrost/Plus microscope slides (Fisher, Pittsburgh, PA). After 
cutting, the slides were dried overnight at +40°C in an oven and stored at +4°C until 
processed. 
 
Paraffin embedded sections were deparaffinized and subsequently dehydrated in xylene 
followed by ethanol and PBS serial rehydration. Antigen retrieval was completed in a 
steamer using 0.01M citrate buffer, pH 6.2, with 0.002M EDTA, for 30 min. After cooling 
for 20 min, slides were washed in PBS 2 times and permeabilized in1% Triton X-100 in 
PBS for 30 min, and subsequently rinsed in PBS. After washing, sections were encircled 
with a PAP pen. Sections were incubated in 10% normal donkey serum, 1% BSA, 0.03% 
Triton X-100, all diluted in PBS, for 30 min to block nonspecific binding sites and rinsed 




The immunofluorescence procedures have been described by our group previously. 113 
Blocked sections were incubated with a primary antibody mix at +4°C, overnight, in a wet 
chamber. The following primary antibodies were used to stain the pancreas: anti-insulin 




anti-somatostatin (1:400, Abcam, #ab53165).  Sections were rinsed in PBS 3 times, 10 
minutes each, and incubated for 2 hr at room temperature in a mix of fluorophore-
conjugated secondary antibodies in wet chamber protected from light. Appropriate 
secondary antibodies were used that were conjugated with DyLight 488 (1:400, Jackson 
ImmunoResearch Laboratories Inc., West Grove, PA), Alexa 555 (1:400, Molecular 
Probes, Eugene, OR), or Alexa 647 (1:400, Molecular Probes). The same solution was 
used to dilute primary and secondary antibodies: 1% NDS, 1% BSA, 0.03% Triton X-100. 
After incubation with secondary antibody, slides were washed in PBS 3 times, 10 minutes 
each, and mounted with anti-fading agent Gel/Mount (Biomeda, Foster City, CA). Stained 
slides were viewed using a Nikon C1Si microscope. Images were captured on a Nikon 
C1Si or C1 Plus confocal microscope, and were analyzed using Nikon software EZ-C1 
3.90 Free viewer.  
 
Immunohistochemistry  
Immunohistochemistry procedures have been described previously. 113 Anti-insulin 
(1:200, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, #sc9168), anti-glucagon 
(1:200, Santa Cruz Biotechnology, #sc13091), or anti-somatostatin (1:200, Abcam, 
#ab15365) primary antibodies were used for pancreas immunostaining. Staining was 
developed using Histostain-Plus Broad Spectrum (AEC) Kit (Invitrogen, Frederick, MD). 
Slides were counterstained with hematoxylin to identify cell nuclei. 
 
After staining, slides were rinsed in deionized water and placed on coverslips in Clear 




immunoreactivity was confirmed by omitting the primary antibody from some sections. 
The staining was observed using a light microscope Nikon Eclipse 80i (Nikon Instruments, 
Melville, NY). Images were analyzed using Adobe Photoshop CZ4 extended software.  
 
Pancreas Digestion 
For organs used to isolate islets, the pancreas was placed on a cooled sterile surgical 
tray for processing. The attached duodenal section was resected from the pancreas and 
discarded, and the mass of the pancreas was recorded. The accessory pancreatic duct 
was located and cannulated using a sterile 18 G, 20 G, or 22 G catheter, depending on 
the size of the ductal lumen. 103 Six pancreata (groups W and TB, Table 3.1) underwent 
a preliminary saline ductal flush and rinse. These pancreata were completely distended 
with saline via the accessory duct and immersed in cold sterile saline solution to purge 
the organ of excess blood. In order to examine the effectiveness of the ductal purging 
technique, four pancreata did not undergo a preliminary ductal saline flush and rinse 
(group NH, Table 3.1). Heparin was not administered in these donors. All pancreata were 
next perfused with freshly prepared collagenase solution (described above) using a 30 
mL syringe and flexible Luer extension set. Phenol red dye was included in the enzyme 
buffer to visually confirm the complete perfusion of enzyme throughout the gland. 
Heparinized and flushed pancreata were further divided into two groups. In the first group 
(group W, Table 3.1), the whole pancreas was filled with collagenase and processed. In 
the second group (group TB, Table 3.1), the head of the pancreas was not perfused by 
ensuring the catheter was only in the main tail/body branch, and subsequently ligating the 




removed, weighed and discarded. The digested tissue mass was recorded for each 
isolation.  
 
Following enzyme perfusion, pancreata were cut into 2-3 cm pieces and divided into 250 
mL polycarbonate flasks containing 10 silicon nitride beads for mechanical disruption. 
Each 250 mL flask contained a maximum of 25 g of tissue. Flasks were then filled with 
additional cold digestion buffer to a total volume of ~250 mL. Finally, the flasks were 
placed in a 38°C shaking water bath at 120 rpm with occasional manual shaking. During 
the digestion process, small samples of the tissue were stained with dithizone to evaluate 
the extent of islet liberation from exocrine tissue. When at least 50% of islets were free of 
exocrine, or no improvement in islet liberation was observed in subsequent samples, 
digestion was stopped by transferring the tissue into a 500 mL centrifuge bottle containing 
250 mL cold RPMI 1640 media with 10% bovine calf serum (BCS). Bottles were placed 
on ice and the tissue was allowed to settle by gravity for 15 minutes. The supernatant 
was discarded and the tissue was transferred to 225 mL centrifuge tubes, rinsed with 
additional RPMI with 10% BCS, and centrifuged at 400 rcf (relative centrifugal force) for 
5 minutes at 4°C. 103  
 
Digestion times were evaluated using a one-tailed student’s t-test to determine if the 
heparin and saline flush treatment resulted in significantly reduced digestion times 
compared to the untreated group. Pairwise comparisons of donor bodyweight, warm 




detect significant differences between the heparin treated and non-treated donor groups. 
Significance was defined as p < 0.05. 
 
Islet Purification 
Tissue pellets were re-suspended in cold HTK-PEG solution and triturated several times 
with a 25 mL serological pipette and then a 30 mL syringe. The tissue was passed through 
a 500 μm steel mesh to remove large, undigested debris. 17 The tissue digest was 
collected in clean 225 mL centrifuge tubes and pelleted at 400 rcf for 5 min at 4°C and 
the supernatant discarded. Pellets were dried by inverting the tubes on sterile gauze for 
60 s and then weighed. The tissue was re-suspended in HTK-PEG solution at an 
approximate concentration of 0.1 g per mL and stored at 4°C for a minimum of 45 min. 
114,115 
 
After the cold incubation period, an initial test gradient purification was performed to verify 
the appropriate density for islet purification. Fifteen mL of tissue/HTK-PEG suspension 
was combined with 6.5 mL of the high osmolality iodixanol stock to bring the density of 
the medium to 1.110 g/mL and incubated on ice for 5 minutes. The tissue digest was 
deposited beneath 25 mL of RPMI with 10% BCS in a 50 mL centrifuge tube to generate 
a two-layer discontinuous gradient. The gradient was centrifuged at 400 rcf for 5 minutes 
at 4°C. The entire supernatant (containing purified islets) was poured in a clean tube and 
centrifuged again while the pellet (containing exocrine tissue) was discarded.  The second 




contamination before processing the remaining tissue.  If necessary, the density of the 
gradient medium was modified in order to achieve a minimum target islet purity of 60%.   
 
Islet purity was evaluated by visual inspection at 24 h after isolation under a light 
microscope using dithizone stain to distinguish islets from non-islet tissues.  116 Dithizone 
stain (Sigma Aldrich) was prepared by dissolving dithizone in dimethyl sulfoxide (DMSO) 
at 10 mg/mL, and then diluting with PBS to a concentration of 0.2 mg/mL, and was added 
to islet suspensions at 10% v/v. To obtain purity, five representative samples from each 
donor were stained and examined via bright field microscopy. Islet purity was estimated 
to the nearest 5% for each sample and the values were averaged to obtain the final purity. 
Pairwise comparisons between the tail/body and whole pancreas groups were made 
using a two-tailed student’s t-test. Significance was defined as p < 0.05. Isolations with 




Isolated canine islets were cultured in 150 mm petri dishes in 25 mL of CMRL 1066 media 
(with a glucose concentration of 5.6 mM) supplemented with 10% fetal bovine serum, 2 
mM glutamine (GIBCO® GlutaMAX, ThermoFisher Scientific), and an antibiotic-
antimycotic (GIBCO® Anti-Anti 100X, ThermoFisher Scientific) at 37 °C and 5% CO2 at 
a maximum density of 5000 islet equivalents per dish. 19,117 Media was exchanged the 





Islet Yield Assessment 
Islet yields of each isolation were calculated according to the standard method of 
conversion to islets equivalents, or “IEQ”, which accounts for the size variation of native 
islets. 23 Due to the size disparity of canine donors, islet yield was also calculated per 
gram of digested tissue and per kilogram of donor bodyweight.  
 
Pairwise comparisons between tail/body and whole pancreas groups of islet yield was 
done using a one-tailed student’s t-test to determine whether yield per gram of digested 
pancreas was significantly higher in the tail/body group. Pairwise comparisons of donor 
bodyweight, warm ischemia time and cold ischemia time were made using a two-tailed 
student’s t-test to detect significant differences between the groups. Significance was 
defined as p < 0.05. 
 
Viability Assessment 
Islet viability was evaluated using a live/dead fluorescence assay.  Islets in PBS were 
stained with calcein AM and PI at 4 μM and 1 μg /mL, respectively and imaged by 
fluorescence microscopy. 19,118 Dithizone stain (described above) was added at 10% v/v 
to distinguish islets from exocrine and ductal tissue, which were not included in the 
viability calculations. Fluorescence images were analyzed using Adobe Photoshop CC. 
The percentage of dead cells was obtained by dividing the number of red pixels 
(propidium iodide) per islet by the total islet pixels. Data are reported as percent viability.  
Viability was assessed between 24 and 72 h after isolation. Twenty-five individual islets 




between the tail/body and whole pancreas groups were made using a two-tailed student’s 
t-test. Significance was defined as p < 0.05. 
 
Glucose Stimulated Insulin Secretion via Static Incubation 
Glucose stimulated insulin secretion (GSIS) of the isolated canine islets was evaluated 
by static incubation of islets in buffers containing varying levels of glucose. All glucose 
solutions were made in an EBSS (Earl’s Balanced Salt Solution) buffer with 0.1% BSA 
and sodium bicarbonate added, pH 7.4 at 37°C. 117 All incubation steps were completed 
at 37 °C at 5% CO2. First, islets were equilibrated to the basal medium of 2.8 mM glucose 
for 1 h. Using Transwell inserts (8.0 um pore size) in a 24-well plate, approximately 50 
islets were transferred to a low glucose condition of 2.8 mM glucose, followed by 22.4 
mM (high) glucose, and finally 30 mM KCl, a standard insulin secretagogue 119 for 90 min 
each. Supernatant media was collected after low, high, and KCl incubations and stored 
at -80 °C until insulin quantification was performed. GSIS was assessed after 3 and 7 
days of culture.  
 
Insulin concentration was determined with alphaLISA insulin assays (Perkin Elmer, 
Waltham, MA) and a EnSpire® plate reader (Perkin Elmer) equipped with the 
corresponding alpha technology. Assays were carried out according to the manufacturer’s 
instructions with insulin standards fit to a 12-point curve fit to a 5-parameter logistic curve. 
Insulin concentration data were then used to calculate stimulation indices, which is the 
ratio of insulin secretion in high glucose to low glucose. Stimulation indices of islets from 




student’s t-test to identify significant differences in insulin secretion between the two 
groups. Significance was defined as p < 0.05. 
 
Results 
Effect of Pre-mortem Heparin and Ductal Saline Flush 
The method reported herein incorporated two additional steps to enhance enzymatic 
digestion of the pancreas compared to previously reported procedures. 103,120,121 First, 
heparin sulfate was administered pre-mortem to prevent blood coagulation within the 
pancreatic tissue after euthanasia. Second, the pancreas was distended with cold saline 
solution and then rinsed by immersion in cold saline followed by enzymatic perfusion. We 
detected no significant difference in donor bodyweight, warm ischemia time, or cold 
ischemia time between the heparinized and non-heparinized donors (Table 3.1). 
Digestion time was significantly reduced when heparin and saline treatments were 
included compared to the untreated group (Figure 3.1). Pancreatic tissues digested 
quickly and uniformly after heparin and ductal saline flush treatments. Without treatment, 
the pancreatic digest contained larger and more granular particles that were unable to 
pass through a 500 μm screen, indicating incomplete and non-uniform digestion. 
Furthermore, isolation results obtained from the untreated pancreata were considered 
unacceptable for further evaluation because they did not meet our minimum criteria of 






Regional Distribution of Endocrine Cells in Canine Pancreas 
The distribution of islets within the pancreas is not uniform in the dog, as reported 
previously. 104,122  Specifically, the body and tail of the canine pancreas has been reported 
to contain more glucagon and insulin-positive cells, indicating more islet tissue compared 
to the head of the pancreas. 21,123 We examined portions of the canine pancreas using 
immunohistochemistry and immunofluorescence.  Figure 3.2 illustrates typical images 
from canine pancreatic sections from the head, body and tail of the pancreas. Insulin 
staining was less frequently noted in the head compared to other sections of the 
pancreas, and was most abundant in the tail region. The same was true of glucagon and 
somatostatin. However, glucagon-positive cells were rare in both the head and body 
sections, and were often found surrounded by the appearance of acinar cells rather than 
other islet cells as shown in Figure 3.2.  
 
To further identify whether glucagon cells were located independently of the islet 
structures in the canine pancreatic head, body and tail, triple-labeled 
immunofluorescence was employed. Typical images are shown in Figure 3.3 from each 
region. In the head, there was no co-localization of the insulin- or somatostatin-positive 
cells corresponded with glucagon staining. In fact, there were almost no glucagon-positive 
cells noted in the head of the pancreas, corresponding to the results noted using 
immunohistochemistry (Figure 3.2).  The body and tail both displayed larger islets with a 
mixture of insulin-, glucagon-, and somatostatin-positive cells. In the body and tail, all 
three cell types were found both in islet structures and as independent cells scattered 




Effect of Pancreas Region on Yield of Islets 
Due to the uneven distribution of islets within the pancreas, we conducted studies to 
determine whether exclusion of the head of the pancreas would improve the efficiency of 
the islet isolation process. Pancreata were divided into two groups for the regional islet 
isolation studies (W and TB), as shown in Table 3.1. In group W, the whole pancreas was 
digested, while only the tail and body of the pancreas were digested in group TB. There 
were no significant differences in the warm or cold ischemia times or donor bodyweights 
between the two groups (W vs TB, Table 3.1). Table 3.2 summarizes the isolation 
outcomes for the two groups, and illustrates that the total tissue mass digested in the 
whole pancreas group was nearly double that in the tail and body group. When the 
average islet yield (IEQ) was normalized to donor bodyweight, there was no significant 
difference in the total islet yield between the two groups (Figure 3.4A).  However, when 
the islet yield was normalized to the actual mass of pancreas digested, isolation from the 
tail/body region was far more efficient (Figure 3.4B).  
 
Islet Purity, Morphology, and Viability 
While yield was greater per gram of tissue when only processing the body and tail of the 
pancreas, the final purity of each preparation was not different between the two 
approaches. Dithizone staining was used to distinguish between islet and non-islet 
tissues. Representative bright field images are shown in Figure 3.5 (top row). Islets from 
both groups displayed typical morphology, indicated by smooth, round edges and strong 
red dithizone staining. Table 3.2 shows that the percentage of islet cells in each 




Islet viability was evaluated after isolation via a fluorescent live/dead assay with a 
representative image shown in Figure 3.5 (bottom row). Green fluorescence staining 
within the islet clusters indicated live cells, and red fluorescence identified necrotic cells. 
The average islet viability for the whole pancreas isolations was 95.5 +/- 0.60 % and for 
the body and tail was 95.4 +/- 0.2 %.  The results demonstrate very good viability of 
isolated islets from both groups and no significant difference between them.  
 
Glucose Stimulated Insulin Secretion 
Islet function was evaluated via glucose stimulated insulin secretion. Islets were 
incubated in low (2.8 mM) and then high glucose (22.4 mM) and the secreted insulin in 
each condition was quantified and normalized to the IEQ. Secretion indices (SI), or the 
ratio of secreted insulin in high glucose to that in low glucose, were measured at 3, and 
7 days post isolation.  Figure 3.6 displays SI values for the whole pancreas and tail and 
body groups. Analysis detected no statistical differences in secretion index between the 
groups at either time point. Secretion indices were greater than or equal to 2 for all 
measurements, demonstrating good secretory function of the islets.  
 
Discussion 
In this series of studies, we describe a combination of techniques for optimizing and 
simplifying canine islet isolation from sub-optimal donor sources. Pancreatic tissues for 
veterinary islet transplantation will likely be from off-site cadaveric donors, and will 
inevitably be exposed to prolonged warm and cold ischemia. Unfortunately, all of these 




Islets are purified via density gradient centrifugation, exploiting their lighter native density 
compared to pancreatic exocrine cells. Periods of warm or cold ischemia cause significant 
edema (swelling) of the pancreatic tissue, which alters the cellular density and thus 
diminishes isolation quality. 81,124 The extended ischemia times inherent to off-site, post-
euthanasia pancreas procurement exacerbate this cellular swelling, often to a point when 
successful isolation of islets is impossible. Fortunately, numerous strategies have already 
been employed in human islet isolation research to prevent and even reverse ischemic 
damage, generally through the use of colloid-containing organ preservation solutions and 
hyperosmotic density gradient media. 16,78,125–128 However, these strategies have been 
applied primarily to beating-heart human donor pancreata processed with specialized islet 
isolation equipment, and are not well known to be effective with canine tissue and under 
the sub-optimal conditions described above. 
 
For these studies, we utilized a modified HTK preservation solution containing 
polyethylene glycol (PEG) as a colloid, because PEG is known to have many protective 
effects against cellular swelling and ischemic injury in general. 129–131 Further, there is 
emerging evidence of the benefits of PEG for islet isolation and transplantation 
specifically. 106,132 Then, we added a hyperosmotic iodixanol stock to this modified HTK 
solution to create a custom, easily adjustable density gradient solution at approximately 
450 mOsm/kg. Mildly hypertonic environments between 400-500 mOsm/kg have been 
shown to selectively increase exocrine tissue density over islets, thus enhancing 




we were able to achieve consistent, high quality islet isolations without the use of the 
Ricordi chamber and other complex, specialized equipment.  
 
Vascular flushing has become standard practice for human pancreas preservation for 
islet isolation, but requires extensive training, and increases the time and cost of pancreas 
procurement substantially. 16,78,108 As such, this technique is not well suited for veterinary 
applications. In lieu of traditional vascular flushing, we incorporated a pre-mortem heparin 
injection followed by a ductal purging step directly prior to enzyme perfusion. Further, the 
treatment reduced average digestion times by 18 min per pancreas, and drastically 
improved isolation outcomes. These results are well in line with previous reports that 
shorter digestion times strongly correlate to both higher numbers of islets recovered per 
pancreas as well as IEQs per gram. 134  
 
In contrast to humans, islet cell distribution and islet morphology are highly 
disproportionate throughout the canine pancreas.  Wieczorek et al. showed that the 
majority of islet cells were located in the left lobe (i.e. tail and body) and were large and 
compact. 104 Conversely, the right lobe (i.e. head) contained mostly single cells and small 
islets, along with pancreatic polypeptide cells. The histological evaluations described here 
further corroborate these findings. Thus, we evaluated the effect of completely omitting 
the head of the pancreas in islet isolation as a means of increasing processing efficiency 
and reducing material costs. Islet yield per gram essentially doubled when only the tail 





To our knowledge, this is only the second report of successful islet isolation from 
deceased canine donors 103, and the first to do so without the use of the Ricordi system 
and with up to 90 minutes of cold ischemia time. Islets isolated by our method were 95% 
viable, had good purity and were responsive to glucose stimulation. We obtained an 
average of 1868 IEQ/g of digested pancreas (tail/body), which compares favorably to the 
median of 608 IEQ/g reported by Vrabelova et al. 103 Woolcott et al. reported yields of 
approximately 3600 IEQ/g, but pancreata in these studies were obtained from heart-
beating donors with no reported cold ischemia. 121 Similarly, Lakey et al. reported a range 
of 3800 – 4490 IEQ/g using a comparable enzyme blend, but again used heart-beating 
donors and did not report any periods of cold ischemia. 135 Unfortunately, these ideal 
experimental conditions are likely unattainable for veterinary applications, and would raise 
considerable ethical concerns. In contrast, our method, which utilized deceased donors 
with extended periods of warm and cold ischemia, acheived yields of greater than 1500 
IEQ/kg of donor bodyweight. Generally, between 5,000-10,000 IEQ per kg are needed to 
reverse diabetes in canines. 67,70,99,136,137 Thus, our method could obtain, from a single 35 
kg canine donor, enough islets to reverse diabetes in a 10 kg recipient.   
 
The implications of these results move the field one step closer to a clinical canine islet 
isolation procedure. There are indubitably other barriers that must be addressed such as 
immunoprotection and quality assurance of grafts. We, and others, continue to work on 
these challenges. Currently we are testing a variety of micro-encapsulation methods to 





In conclusion, we have demonstrated a simple and repeatable method for isolating quality 
canine islets from deceased donors. Furthermore, our findings, in corroboration with 
previous histological studies 21, suggest that the head of the canine pancreas contains 
almost no recoverable islet tissue, and may be safely omitted from the isolation process. 
While efforts to improve upon these processes should certainly continue, these results 
represent a promising step forward in overcoming one of the most critical barriers to 










Figure 3.1. Effect of heparin and ductal flush. 
The effects of pre-mortem heparin and post-mortem ductal saline flushing steps on enzymatic 
digestion were evaluated. Digestion times were reduced significantly when these steps were 
incorporated (* denotes significance, p= 0.01; N=6 for the Hep-Saline group and N = 4 for the 







Figure 3.2. Immunohistochemistry of canine pancreas by region. 
Tissue sections of the three major regions of the pancreas were stained with antibodies for 
insulin (top row), somatostatin (center row), and glucagon (bottom row) to identify the three 
major islet cell types (beta, delta, and alpha cells, respectively). Insulin positive cells were 
primarily located in the body (center column) and tail (right column), with the highest 
concentration and largest sized clusters in the tail. Insulin positive cells in the head of the 
pancreas (left column) were far less prevalent and occurred primarily in very small clusters or 
single cells.  Similar patterns were observed for somatostatin, while glucagon positive cells 
were present in extremely low numbers in the head and body and often appeared as isolated 
single cells. Glucagon images are displayed at higher magnification to better illustrate single 






Figure 3.3. Immunofluorescence of canine pancreas by region. 
Pancreatic sections were triple-stained with fluorescent antibodies for insulin (green), glucagon 
(red), and somatostatin (blue) to identify variations in the co-localization of pancreatic cell types 
within different regions of the pancreas. Interestingly, glucagon-positive cells were rarely 
observed in the head of the pancreas, and were typically not co-localized with insulin- and 
somatostatin-positive cells.  Insulin- and somatostatin-positive cells were co-localized in the 
head region, and were typically in clusters of only a few cells. In contrast, the tail and body 
region contained structures consisting of large numbers of cells that predominantly contained 
all three endocrine cell types, with the highest concentration and largest clusters of cells located 







Figure 3.4. Effect of pancreas region on islet yield. 
The effect of processing only the tail and body of the pancreas were evaluated. No significant 
difference in islet yield was observed when the whole pancreas was processed versus only the 
tail and body (A). IEQ values were normalized to donor bodyweight (per kg) to account for the 
high variability of canine donor size. Islet yield per gram of tissue digested was significantly 
improved by omitting the head of the pancreas from processing (B) (* denotes significance, p 






Figure 3.5. Morphology and viability of isolated islets. 
Morphology and viability of isolated islets were evaluated. Islets isolated from both groups 
(whole pancreas or tail/body only) had healthy capsules and stained deep red with dithizone, 
which binds to insulin within the islet (top row). Islets were co-stained with a live (green 
fluorescence) and dead (red fluorescence) stain (bottom row). Islets showed strong green 






Figure 3.6. Glucose stimulated insulin secretion. 
Islet function was evaluated over time via glucose stimulated insulin secretion assay. Islets 
were exposed to low then high glucose, and the secreted insulin in each condition was 
quantified to calculate a stimulation index, or SI (high secretion/low secretion). SI’s were 
calculated separately for tail/body isolations and for whole pancreas isolations. Differences in 





Animal ID Breed Gender Age(years) BW(kg) WIT(minutes) CIT(minutes) 
Whole Pancreas 
W1 Lab/Pitbull M N/A 21 17 90 
W2 Hound M 2 25 7 86 
W3 Pitbull Mix M 2 20 13 72 
Average - - - 22.0 12.3 82.7 
SE - - - 1.7 2.9 5.5 
Tail and Body 
TB1 Shepherd Mix M 1 21 23 75 
TB2 Hound M 2 31 10 72 
TB3 Wheaton Terrier M 2 20 23 87 
Average - - - 24.0 18.7 78.0 
SE - - - 3.5 4.3 4.6 
No Heparin/Ductal Flush 
NH1 Pitbull Mix M 0.5 10 28 77 
NH2 Pitbull/Shar Pei Mix F 2 23 25 72 
NH3 Shepherd Mix F 5 20 20 90 
NH4 Chow Mix M 4 10 20 150 
Average - - - 15.9 23.2 97.2 
SE - - - 3.3 2.0 18.0 
Histological Study 




- - - 20.7 18.7 86.9 
SE - - - 1.9 1.9 6.7 
 
Table 3.1. Pancreas donor information. 
Abbreviations: W, whole pancreas; TB, tail and body; NH, no heparin/ductal flush; IHC, 
immunohistochemistry; N/A, not available; BW, bodyweight; WIT, warm ischemia time; CIT, 






Animal ID Tissue Mass Digested (g) Total IEQ Purity (%) 
Whole Pancreas 
W1 40 29,014 76 
W2 57 39,134 63 
W3 40 36,283 73 
Average 45.7 34,810 70.7 
SE 5.7 3,012 3.9 
Tail and Body Only 
TB1 12 16,964 67 
TB2 35 49,335 74 
TB3 23 62,626 74 
Average 23.3 42,975 71.7 




34.5 38,892 71.2 
SE 6.3 6,474 2.1 
 
Table 3.2. Islet isolation outcomes by pancreas region 





CHAPTER 4: Evaluation of a Hyaluronic Acid Hydrogel as 




Alginate has long been the material of choice for immunoprotection of islets for its low 
cost and ability to easily form microspheres. Unfortunately, this seaweed-derived material 
is notoriously prone to fibrotic overgrowth in vivo, resulting in premature graft failure. The 
purpose of this study was to test an alternative hyaluronic acid and denatured collagen 
hydrogel (HA-COL), for in vitro function, viability and allogeneic islet transplant outcomes 
in diabetic rats. In vitro studies indicated that the HA-COL gel had diffusion characteristics 
that would allow small molecules like glucose and insulin to enter and exit the gel, while 
larger molecules (70 and 500 kDa dextrans) were impeded from diffusing past the gel 
edge in 24 hours. Islets encapsulated in HA-COL hydrogel showed significantly improved 
in vitro viability over unencapsulated islets and retained their morphology and glucose 
sensitivity for 28 days. When unencapsulated allogeneic islet transplants were 
administered to the omentum of out-bred rats, they initially were normoglycemic, but by 
11 days returned to hyperglycemia. Immunohistological examination of the grafts and 
surrounding tissue indicated strong graft rejection. By comparison when using the same 
out-bred strain of rats, allogeneic transplantation of islets within the HA-COL gel reversed 
diabetes long-term and prevented graft rejection in all animals. Animals were sacrificed 
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at 40, 52, 64, and 80 weeks for evaluation, and all were non-diabetic at sacrifice. 
Explanted grafts revealed viable islets in the transplant site as well as intact hydrogel with 
little or no evidence of fibrotic overgrowth or cellular rejection. The results of these studies 
demonstrate great potential for HA-COL hydrogel as an alternative to sodium alginate for 






Islets transplantation will most likely remain an experimental treatment while 
immunosuppressive therapy is required. The reality is that, for the majority of type-1 
diabetics, the health risks of chronic immunosuppression may outweigh the potential 
enhanced quality of life granted by an islet transplant. Indeed, between 1999 and 2007, 
less than 400 islet transplantations were performed in the United States, while prevalence 
of this disease stands at approximately 1.25 million cases of type-1 diabetes nationwide. 
138,139 Extensive effort has been put forth to address this striking treatment gap. Numerous 
strategies have been employed toward eliminating the requirement of chronic 
immunosuppression, including immunomodulation via antigen-specific regulatory T cells, 
patient specific stem cell-derived autologous beta cells, and a trove of immunoprotective 
devices, capsules, and coatings. 76,140,141 Of these, immunoprotection by hydrogel 
encapsulation has received the greatest consideration as one of the most readily 
translatable approaches for the clinic.  
 
Immunoprotection by gel encapsulation, in general, provides two key advantages. First, 
the extensive body of research surrounding this concept spans more than three decades, 
providing a wealth of fundamental knowledge and robust evidence of safety and efficacy 
to better facilitate translation. 47,54,142 Second, immunoprotection enables transplantation 
of allo and xenogeneic (e.g. porcine) islets, the latter a promising approach to the critical 
barrier of donor scarcity. 143,144 To this point, immunoprotective hydrogel systems could 
have tremendous future utility in the safe delivery of stem cell-derived islet surrogates. 145 




immunoprotection strategies along with several attempts to commercialize them. 76 Of the 
various strategies, hydrogel encapsulation remains a leading approach to achieving 
widespread clinical success of islet transplantation.  
 
Inexpensive alginate hydrogel microcapsules have dominated the islet encapsulation 
realm since their introduction in 1980. 47 The nearly instantaneous gelation mechanism of 
these seaweed-derived alginate polymers enables simple fabrication of microcapsules 
that can be easily injected into a patient. Furthermore, these capsules have been 
established as both durable and non-toxic to host organisms. 55,101,142  However, due to 
the foreign nature of the material, they are notoriously prone to fibrotic overgrowth, 
ultimately leading to necrosis of encapsulated cells and premature graft failure. 48,55,56 
Some progress has been made with the development of ultra-purification processes, 
surface treatments, co-encapsulated materials, and more stringent control of capsule 
microstructure, but despite these advances, the performance of alginate microcapsules 
still does not meet the clinical needs for islet transplants. 48–50,101,146 
 
Recently, native, “raw”, and biomimetic materials have been gaining attention as 
improved cellular scaffolds and delivery systems. 147,148 Such materials are intrinsically 
biocompatible with lower probability of inducing fibrosis, and may better sustain or direct 
cellular function of encapsulated tissues. Lim et al. demonstrated enhanced in vitro 
function and survival of rat islets within a self-assembling biomimetic peptide gel. 89 Liao 
et al. achieved similar results using an injectable saccharide-peptide gel. 149  In yet 




syngeneic mice at a 40% reduction in islet dose. 88 However, these advanced, bioinspired 
hydrogels typically degrade too quickly to be effective for long-term immunoprotection of 
islet transplants.  
 
Another material of particular interest for this application is hyaluronic acid (HA). 
Hyaluronic acid-based hydrogels have been steadily gaining recognition as an interesting 
class of biomaterial for tissue engineering and cell therapy applications due to their unique 
mechanical and biological properties. 90–92 In 2009, Vanderhooft et al. described the 
versatile rheological characteristics and tunable durability of a hydrogel system comprised 
of thiolated HA and denatured collagen (COL) and a polyethylene glycol diacrylate 
(PEGDA) cross-linker. 93 These HA-COL derived hydrogels are easily prepared under 
physiological conditions with shear moduli ranging from 11 to 3500 Pa. A commercially 
available version of this gel, sold under the brand HyStem-C, has recently been used in 
vivo for myocardial infarct repair in SCID mice and for osteochondral defect repair in 
rabbits. 94,95 
 
In light of the properties of this HA-COL derived hydrogel, the present study sought to 
evaluate this biomaterial as a replacement for alginate hydrogels in encapsulated islet 
transplantation, particularly with regard to graft failure related to fibrosis.  Unlike previous 







Canine Islet Isolation 
Pancreata were obtained from canine donors at local veterinary clinics from animals 
scheduled for euthanasia for other purposes and with no known pancreatic disorders.  
Euthanasia was performed by the licensed veterinarian overseeing the care of each 
animal, and the clinical veterinarian confirmed death with loss of heart function.  Collection 
of the donor pancreata after death from animals euthanized for reasons other than tissue 
procurement, was determined to be exempt from review by the Institutional Animal Care 
and Use Committee of the University of Kansas Medical Center. Canine islets were 
isolated from donors using a method adapted from Vrabelova et al. 103 Pancreata were 
removed after euthanasia at the clinic and transported to the laboratory on ice for islet 
isolation. Pancreata were digested with Liberase T-Flex (Roche Custom Biotech, 
Indianapolis, IN) and purified by discontinuous density gradient centrifugation with an 
iodixanol/HTK based density gradient medium (OptiPrep, Cosmo Bio USA, Inc., 
Carlsbad, CA), as is reported elsewhere. 111 The isolated canine islets were cultured in 
CMRL (Connaught Medical Research Laboratories) 1066 media supplemented with 10% 
fetal bovine serum, 2 mM glutamine, and an antibiotic-antimycotic at 37 °C and 5% CO2. 
Islets were quantified by conversion to islet equivalents (IEQs) using standard methods. 
23  Islet purity was evaluated via dithizone staining (0.2 mg/mL dithizone in PBS), and 






Rat Islet Isolation 
The use of rats for islet isolation and transplantation was approved by the Institutional 
Animal Care and Use Committee of the University of Kansas Medical Center. Islets were 
isolated from pancreata were procured from male and female Sprague-Dawley rats by 
collagenase digestion followed by discontinuous density gradient centrifugation with a 
Ficoll-based density gradient medium (Histopaque 1119 and 1077, Sigma Aldrich) as 
previously described. 17,18,150 Islets were quantified and cultured as described above.  
 
Molecular Diffusion in HA-COL Gels 
For diffusion studies, HA-COL hydrogels (HyStem-C, ESI Bio, Almeda, CA) were 
prepared according to the manufacturer’s instructions with PEGDA as the cross-linker 
and poured into standard 24-well plates using custom silicone dividers to create gels with 
a single exposed vertical edge to facilitate uniform lateral diffusion. Gels were stored in 
phosphate buffered saline (PBS) overnight prior to testing to allow hydrogel swelling.  
Gels were approximately 5 mm in height at equilibrium swelling. 
 
Molecular diffusion into HA-COL hydrogels was examined via fluorescein isothiocyanate 
(FITC) labeled dextrans of increasing molecular weight (dextran-fluorescein 3, 70, and 
500 kDa, Molecular Probes, Eugene Oregon). Wells were loaded with FITC-dextran 
solution (0.1 mg/mL in PBS), and fluorescence at the gel/liquid interface was monitored 
for 24 hours in a Cytation 5 Cell Imaging Multi-Mode Reader (Biotek Instruments, Inc). 
Care was taken that the FITC-dextran solution did not cover the top of the gels to prevent 




the fluorescent micrographs using NIH ImageJ (black = 0 intensity) to quantify 
fluorescence intensity at given x coordinates within the gels. Specifically, the x 
coordinates were chosen to represent 200, 500 and 1000 µm from the edge of the gel 
with y values representing the average (line analysis) across the gel. Data are the average 
gray value of all pixels in the y-direction at a given x coordinate along the micrographs. 
Data were normalized to the average gray value of the surrounding medium outside the 
gel.   
 
HA-COL Gel Encapsulation 
HA-COL hydrogels were prepared according to the manufacturer’s instructions for 
encapsulating cells (HyStem-C, ESI Bio, Almeda, CA). Canine islets were suspended in 
HA-COL gel precursor at approximately 5000 IEQ/mL. IEQ (islet equivalent) is the 
standard measure of islet volume with 1 IEQ equating to a spherical islet of 150 mm in 
diameter.  23 The cross-linker solution (PEGDA, MW 3,400 in PBS) was added and the 
suspension was thoroughly mixed. Finally, the gel precursor containing islets was 
distributed in 5 μL aliquots into 24-well non-tissue treated plates. Each well contained one 
5 μL gel/islet construct with approximately 25 IEQ per gel. Gels were allowed to cross-
link for 60 minutes. Subsequently, 500 μL of CMRL culture media (described above) was 
added to each well. Final constructs contained 1% gel polymer by weight.  
 
Alginate Encapsulation  
Ultrapure, sterile “RGD” conjugated sodium alginate (Novatech MVG GRGDSP peptide 




deionized water containing 300 mM mannitol (to maintain isotonicity) at a concentration 
of 1% by weight to match that of the HA-COL gels. Islets were suspended in the alginate 
solution at approximately 5000 IEQ/mL, and 5 μL droplets were added to individual wells 
of 24-well non-tissue treated plates containing 2.0 mL of cross-linking solution (100 mM 
calcium chloride, 5 mM barium chloride, and 5 mM HEPES at pH 7.4).  Spherical gels 
formed upon contact with the cross-linking solution, and were allowed to cross-link for 10 
minutes under mild orbital agitation. Gels underwent a 10-minute hardening phase in 
HBSS with 10 mM calcium chloride. Finally, the hardening solution was removed from 
each well and replaced with 500 μL of CMRL islet culture medium. All islets were 
encapsulated between two and four days after isolation and incubated at 37°C and 5% 
CO2 in the aforementioned CMRL-based islet culture medium. Media was exchanged 
50% by volume 3 times/week in all groups, including non-encapsulated controls.  
 
Islet Morphology, Viability, and Survival  
Color micrographs of dithizone (DTZ)-stained islets were taken to evaluate islet 
morphology over long-term culture (Axio Vert.A1 Inverted Microscope, Zeiss 
International).  
 
Encapsulated islet viability and long-term survival was assessed in all groups at 3, 7, 14, 
and 21 days after encapsulation via propidium iodide staining and fluorescence 
microscopy (Cytation 5 Cell Imaging Multi-Mode Reader, Biotek Instruments, Inc). 118 




elsewhere. 19 Results shown are the average viable cell fraction of at least 25 individually 
analyzed islets pooled from two separate islet donors for each group at every time point. 
 
Glucose Stimulated Insulin Secretion  
Glucose stimulated insulin secretion (GSIS) was tested on days 3, 7, 14, 21, and 28 using 
a method adapted from the standard Integrated Islet Distribution Program protocol. 151 
Unencapsulated (control) islets were tested in Transwell inserts (8.0 um pore size). The 
islets within the inserts were moved between glucose solutions using sterile forceps after 
each incubation step. Conversely, islet gels remained in their original wells and glucose 
solutions were exchanged with a micropipette.  
 
Glucose solutions were made in an EBSS (Earl’s Balanced Salt Solution) buffer with 0.1% 
BSA and sodium bicarbonate added, pH 7.4 at 37 °C. Incubation in different glucose 
concentrations was done at 37 °C and 5% CO2. Islets were first equilibrated to the basal 
medium with 2.8 mM glucose for one hour then exposed to fresh 2.8 mM (low) glucose 
and 22.4 mM (high) glucose for 90 minutes each. Supernatant media was collected after 
each incubation and stored at -80 °C until insulin quantification was performed. Tests 
were performed in triplicate on islets from three different canine donors for all 
experimental groups. Insulin concentration was quantified via Perkin Elmer alphaLISA 
insulin assays in conjunction with a Perkin Elmer EnSpire® plate reader. All assays were 
performed in triplicate according to the manufacturer’s instructions using a 12-point 
standard curve fit to a 5-parameter logistic curve. Insulin concentration data were 




Diabetic Rat Models  
Outbred streptozotocin-induced diabetic (immune-competent) Sprague-Dawley rats were 
generated as allogeneic islet transplant recipients as described previously. 118 Diabetes 
was defined as an average non-fasting blood glucose (NFBG) above 300 mg/dL over 
three consecutive daily readings. Four diabetic rats received immunoprotected 
(encapsulated) islet transplants within the HA-COL gel and two received islets without gel 
as controls to validate allo-rejection in the present model.  
 
Three diabetic rats were given sham surgeries (i.e. without islets) as diabetic controls. 
Three non-diabetic rats were also included to monitor long-term blood glucose levels in 
aging rats.  
 
Islet Transplantation in HA-COL Hydrogel and Non-encapsulated Controls 
Rat surgeries followed our previously published protocols. 17,18 Briefly, animals were 
anesthetized by ketamine/xylazine and isoflurane (as needed), positioned in dorsal 
recumbency, and abdominal fur was shaved and surrounding skin sterilized with iodine. 
A vertical midline incision was made through the abdominal muscle, and the stomach 
and greater omentum were gently exteriorized and placed on a small sterile pad. A thin 
layer of HA-COL gel precursor solution containing the PEGDA cross-linker was applied 
to the entire omentum and was allowed to cross-link until the gel solution was no longer 
fluid. Islets, suspended in approximately 200 μL of gel precursor, were applied to the 
omentum on top of the base gel layer. Care was taken that the islets were located near 




sufficient time to cross- link and the omentum was folded into a pouch-like structure and 
sutured onto the stomach wall. Finally, the stomach/gel/omentum construct was gently 
returned into the peritoneal cavity and the abdominal incision was closed.  
Islets were transplanted at a minimum dose of 10,000 IEQ/kg into the omentum for all 
recipients. For encapsulated transplants, a thin layer of blank HA-COL gel was applied to 
the omental surface, followed by deposition of the islets suspended in HA-COL gel 
precursor. After gelation was complete, the omentum was sutured to the stomach wall to 
secure the transplant. For animals receiving transplants without hydrogel, islets were 
mixed with a sterile microfribrillar collagen hemostat (INSTAT MCH, Ethicon, Inc. 
Somerville NJ) to form a paste-like substance to hold the islets in place.  
 
Animal Monitoring 
Non-fasting blood glucose (NFBG) measurements were taken daily for the first 14 days 
post-transplant or until graft failure was observed, in which case the animals were 
sacrificed. Over time, the frequency of glucose readings was reduced to a minimum of 
once per week. Graft failure was defined as a return to a diabetic state as described 
above.  
 
Graft Explantation and Evaluation 
Upon sacrifice, the omenta of transplant recipients were removed and preserved for 
histological evaluation. The preserved tissues were embedded in paraffin and sectioned 




H&E or a triple fluorescent stain for insulin, glucagon, and somatostatin as described 
previously. 113 Micrographs were examined to assess islet health, morphology, and cell 
composition at the transplant site, and to evaluate biocompatibility and durability of the 
HA-COL gel. For cell composition analysis, every fifth section was evaluated to ensure 
that cells were not counted multiple times, and a total of 70 unique islet sections were 
counted. When a potential overlapping islet was identified, its cells were not analyzed. 
 
Data Analysis 
Viability data were evaluated for significant differences by two-way repeated measures 
ANOVA. Pairwise comparisons were evaluated via the Holm-Sidak test for significant 
differences between individual group means. Significance was defined as p<0.001 for 
these comparisons as the data did not pass assumptions of normality or equal variance. 
Insulin secretion data was evaluated for significant differences by two-way repeated 
measures ANOVA because tests were repeated at each time point on the same sets of 
islets. Pairwise comparisons were not evaluated for insulin secretion data as the primary 
ANOVA was not significant. 
 
Results 
Diffusion in HA-COL Hydrogels 
Micrographs of diffusion using fluorescent dextrans were acquired over a 24-hour period 
(Figure 1). Diffusion of the 3 kDa probe was very rapid, with significant penetration into 
the gel after just two minutes. Little diffusion of both 70 kDa and 500 kDa probes was 




even after 24 hours of incubation. Interestingly, accumulation of the 70 kDa probe near 
the gel edge was observed and appeared to increase with time, as indicated by more 
intense fluorescence relative to the surrounding medium. Some accumulation of the 500 
kDa probe near the gel edge also appeared to be present at later time points, but was 
minor. Edge accumulation was not observed with the 3 kDa probe.  
 
Images were further analyzed by quantifying the relative fluorescence intensity (pixel 
intensity) at various distances from the gel edge over time, normalized to the fluorescence 
of the liquid medium. Figure 2 provides histograms of the fluorescence intensities of the 
probes over time at 200, 500, and 1000 μm from the gel edge. All probes eventually 
showed substantial diffusion to 200 μm after 24 hours, with the 3 kDa probe reaching 
equilibrium with the medium by the 90-minute time point. At 5 and 24 hours, the 70 kDa 
dextran intensities were 125% and 166% of the medium at 200 μm, respectively, 
corroborating the fluorescence accumulation observed near the interface. By comparison, 
the 500 kDa probe showed 68% and 90% relative fluorescence at the same time points. 
Fluorescence of 3 kDa probe at 1000 μm was detected quickly at only 10 minutes, 
surpassed 50% relative intensity by 90 minutes, and was equal to that of the liquid 
medium at the 24-hour time point. There was negligible fluorescence measured from the 
70 and 500 kDa probes at 1000 μm until the 60-minute time point, and relative 






Viability and Survival of Encapsulated Islets 
The percentage of viable canine islet cells on day 3 was consistent across all groups as 
no significant differences were detected and all were between 97 and 98%. Differences 
in cell survival were non-significant through day 7 of the study period, though the HA-COL 
gel groups showed a slight increase in the viable cell fraction over day 3 values (Figure 
3). On days 14 and 21, cell viability was statistically higher in both gel groups compared 
to the controls, though viability was still over 97% for each group. 
 
Encapsulated Islet Morphology 
Figure 4 displays representative micrographs of encapsulated and non-encapsulated 
control islets stained with dithizone at 3 and 21 days in culture. Images of alginate-
encapsulated islets were cloudy due to the optical properties of the alginate material. 
Islets in all groups appeared healthy and showed robust dithizone staining over the 
duration of the study. In the gel groups, islets generally remained separated from one 
another as well as from exocrine and ductal tissue carried over through the islet isolation 
process.  However, in the control unencapsulated group, islets (dark red stained) were 
more likely to fuse to remnant ductal and/or exocrine tissue (brown, unstained) present in 
the culture dish, as seen in the left column of Figure 4. By day 21, cells appeared to be 
sloughing off from unencapsulated (control) islets but not the islets in gel (Figure 4, 
bottom row), which is consistent with the increased cell death observed in the control 
group at later time points. While single cells were also seen in the HA-COL images, they 
were, most likely, small tissue debris/fragments generated during the islet isolation 




debris was removed during media exchanges. Thus, on day three, the control islets 
appeared clean compared to the gel groups. At day 21, however, cells in the control group 
appeared to originate directly from the islets, where in the HA-COL group, single cells 
were isolated and appeared similar to those in the day 3 images.   
 
Glucose Stimulated Insulin Secretion 
A common measure of islet function is the “stimulation index” (SI): the ratio of secreted 
insulin at high (22.4 mM) to low (2.8 mM) glucose. The SI values were between 2 to 6 
throughout the study, indicating that the islets were able to sense glucose and release 
insulin appropriately (Figure 5). Due to substantial variation in the data within and 
between groups, no statistically significant differences in SIs were detected at any time 
point.  
 
Novel Method of Encapsulated Islet Transplantation 
While in vitro work with the hydrogel was conducted using canine islets, transplantation 
studies into diabetic rats were designed to determine the degree of graft rejection within 
animal species, because xenotransplantation adds additional confounding complications 
152 even when encapsulated. 153,154 Thus, rat islets were encapsulated to be transplanted 
into diabetic rats.  Due to the slow-hardening properties of the HA-COL gel, a new method 
of bulk encapsulation had to be developed. As described in more detail in the Methods 
section, a thin layer of HA-COL gel precursor solution containing the cross-linker 
(PEGDA) was applied to the entire omentum and given time to harden (Figure 6A). Islets 




locating the islets near clearly visible blood vessels to maximize nutrient exchange. The 
islet gel layer was again given time to crosslink so that islets were attached to the base 
later of gel.  Next the omentum was folded and sutured to the stomach wall, creating a 
pouch (Figure 6C), which was then returned to the peritoneal cavity. 
 
Allogeneic Rejection Model Validation (non-encapsulated islet transplants) 
In order to validate the presence of graft rejection in the outbred rat model, diabetic rats 
received allogeneic islet transplants without hydrogel.  Recipients were non-diabetic 
within 2 days following transplantation and displayed normal NFBG, shown in Figure 7. 
On day 8, NFBG levels began to sharply increase in the control animals and by day 11 
the rats were overtly diabetic. By comparison, diabetic sham rats failed to have a single 
blood glucose reading within the normal range (Figure 7).  
 
Non-encapsulated omental transplants were recovered after graft failure was confirmed. 
Tissue from a healthy, non-diabetic rat omentum, stained with H&E, is also shown for 
comparison, predominantly composed of acellular fat deposits and blood vessels (Figure 
8A). A representative image of the explanted tissue, is displayed at low and high 
magnification (Figure 8B & C, respectively). Explanted grafts contained areas with large 
populations of densely packed nuclei with very little cytoplasm, indicative of a massive 
infiltration of lymphocytes and associated graft rejection. Furthermore, no islets could be 






Encapsulated Islet Transplantation Outcomes 
When diabetic rats were transplanted with HA-COL encapsulated islets, all were insulin 
independent and considered non-diabetic immediately following transplantation. Average 
NFBG of the encapsulated transplant recipients over 1 year are shown in Figure 9. Data 
beyond 40 weeks include only 3 animals, as one was sacrificed at that time. Three of 
these rats were well controlled with no measured excursions falling within the diabetic 
range.  The fourth rat had occasional values in the 200-250 range in the first 50 days, but 
those normalized from that time point forward to termination at 52 weeks.  
 
The HA-COL gel transplanted animals were sacrificed for ethical reasons when 
indications of poor health, not related to diabetes, were observed. Axillary and mammary 
tumors were the primary justification for early termination in these studies among other 
neoplastic lesions. Such tumors are common in this strain when the animals reach 
advanced ages. 155 When possible, the islet grafts were recovered at the time of sacrifice 
and preserved for evaluation. No gel was noted in any portion of the peritoneal cavity 
outside of the omentum pouch. 
 
Histological Evaluation of Explanted Encapsulated Islet Grafts  
Explanted islet graft sections stained with H&E revealed intact hydrogel, characterized by 
light blue/purple acellular regions adjacent to the typical adipose tissue of the omentum 
(Figure 10). Minimal eosin positive staining around the perimeter of the gel indicated a 
lack of fibrosis. Figure 11A contains representative immunofluorescence images of an 




three major islet cell types. The average percent composition of the beta/alpha/delta cells 
from 70 islet sections from the explant is shown (Figure 11B).  
 
Discussion 
This study evaluated the potential of a HA-COL hydrogel as an encapsulant to improve 
long-term islet transplantation without immunosuppression. While HA hydrogels are 
becoming increasingly common in tissue engineering research, they have, to our 
knowledge, never been used for encapsulation and immunoprotection of pancreatic islets.  
 
Immunoprotective materials must facilitate diffusion of nutrients and signaling molecules 
(e.g. glucose and insulin) while also preventing direct contact between immune cells and 
the encapsulated cells. Thus, we evaluated the diffusional properties of the HA-COL gel 
using fluorescent dextrans. A small 3 kDa dextran diffused rapidly into the hydrogel, 
suggesting that insulin would encounter little diffusional resistance (MW ~ 5.8 kDa). 
Interestingly, we observed marked accumulation of the 70 kDa probe at the gel/liquid 
interface. Thus, the probe was able to enter the gel fairly readily, but there was likely 
some form of thermodynamically favorable interaction between the large dextran and the 
hydrogel (e.g. conformational effects or van der Waals forces) that did not exist in 
sufficient magnitude with the smaller 3 kDa probe. 156 This may suggest that moderately 
sized proteins, such as albumin (~66.5 kDa) could diffuse into the gel in vivo, but with 
marked attenuation at greater diffusion lengths. The 500 kDa probe exhibited the least 
extensive diffusion, but was not blocked from the gel matrix entirely. However, it is 




and mostly linear polymers, whereas immunoglobulins and antibodies are rigid, globular 
structures. Pluen et al. demonstrated that diffusion of linear polymers into hydrogels was 
substantially greater than globular proteins of similar molecular mass, noting that the latter 
became quickly entrapped within gel pores. 157 Thus, diffusion of high molecular weight 
globular proteins through this gel would likely be more limited compared to the FITC-
dextran probes. While we did not characterize the average pore size of the hydrogels 
explicitly, infiltration of the 500 kDa dextran probe suggests that the average pore size of 
the HA-COL gel is large compared to other common hydrogels like those made from low 
molecular weight PEGDA. For example, Durst et al. described a 15% PEGDA (MW 3.4 
kDa) gel with an average pore size of 5.94 nm. 158 By comparison, the reported 
hydrodynamic radius of a 500 kDa dextran is 15.9 nm. 46 Furthermore, because porosity 
and pore size are strongly correlated to cross-link density and polymer mass fraction of 
the hydrogel, these parameters could be easily controlled, if desired, by simply increasing 
the concentration of HA/COL, PEGDA (the cross-linker), or both.    
 
When comparing the long-term islet viability, the alginate-RGD gel performed as well as 
the natural HA-COL gel over 3 weeks. The results were somewhat surprising given the 
more biocompatible characteristics of HA-COL. This result may be attributable to the RGD 
motif present in both gels, which has a well-documented benefit to islet viability in vitro.  
89,159,160 Cheng et al. evaluated cardiosphere-derived cells in the same HA-COL gel with 
and without the RGD-containing (COL) component, and found that the HA-COL gel led 
to higher cell survival than the gel with HA alone. 95 While our data did not show a 




HA-COL gel facilitated a significant reduction in cell death over unencapsulated islets 
during long-term culture. 
 
Islets in all groups, including controls, remained responsive to glucose stimulation 
throughout the entire 28-day study. Other publications have shown that cultured islets 
generally have near or complete loss of GSIS after 14 days, 23,24 but we did not see this 
in our studies. One difference in our procedure was the presence of acinar or ductal cells 
in our cultures, which have been shown to possess pro-islet properties, compared to 
typical in vitro studies done with highly pure or handpicked islets. 161 In fact, Murray et al. 
reported that pancreatic duct-derived epithelial cells improved glucose sensitivity in vitro 
compared to control islets, which lost nearly all response after 10 days. 162 Thus, it is 
possible that the presence of some non-islet cell types carried over from the isolation 
process contributed to the unanticipated persistence of islet function in the control groups. 
Overall, the results of this study may suggest that, at least in vitro, any beneficial effects 
of encapsulating materials on islet function are much less potent than cell-derived signals. 
However, additional studies would be needed to confirm this hypothesis. 
 
Allogeneic transplants of islets in HA-COL hydrogels into diabetic rats reversed diabetes 
and showed no evidence of graft rejection or fibrosis in the recipients for up to 18 months. 
Immunofluorescence staining of explanted HA-COL grafts revealed healthy islets 
containing all three major islet cell types in a ratio and spatial distribution that is 
characteristic of healthy rat islets. 118,163 These results corroborate the excellent glycemic 




immunoprotective capacity of the HA-COL gel. This is encouraging given the long history 
of biocompatibility issues surrounding alginate-based islet transplants, which are prone 
early graft failure due to fibrosis 54–59, although some progress has been made in this 
regard through advanced alginate purification and capsule optimization protocols. 48–53 
However, the processes for improving alginate biocompatibility are complex and 
expensive; thus, an alternative encapsulant for islet transplantation is appealing.   
 
There are clearly differences between the bulk-gel transplantation method described here 
and alginate microsphere-based transplants. Advantageously, we found that the targeted 
deposition of islets to the highly-vascularized regions of the omentum produced 
consistent, high quality transplant outcomes. However, this method is of course more 
invasive and less convenient than a simple injection of alginate beads, and therefore not 
ideal for clinical use. Considering this, our lab is currently developing a novel method for 
producing uniform islet-microspheres using this HA-COL gel, enabling a more clinically 
relevant delivery of the material. 
 
The bio-stability of encapsulating materials is a critical factor for maintaining long-term 
immunoprotection of an islet graft. Several extracellular matrix- or bio-inspired hydrogels 
have been evaluated for islet transplantation, including self-assembling peptide gels and 
a VEG-F loaded PEG maleimide gel. 88,89,149 While these gels improved engraftment, they 
degraded much too quickly to be appropriate for long-term function in vivo. Conversely, 




by modifying the component concentrations to improve gel strength further. For example, 
Vanderhooft et al. showed that when concentrations of HA and PEGDA were increased 
from 0.4% and 0.2% (formulation used in this study) to 1.6% and 1.6%, respectively, the 
shear modulus increased from 37 to 3500 Pa. 93 Even at the relatively low gel 
concentration used in this study, the HA-COL gel persisted for up to 18 months in the rat 
omentum. 
 
In conclusion, this study demonstrates the potential of an HA-COL derived hydrogel as 
an effective alternative to alginate for long-term immunoprotected islet transplantation at 
a time when clinical outcomes of alginate encapsulated islet transplants have been 
disappointing. These promising results support further investigation of this HA-COL 










Figure 4.1. Diffusion into HA-COL hydrogels.  
Fluorescence micrographs of 3 kDa (left), 70 kDa (center), and 500 kDa (right) FITC-dextran 
diffusion into HA-COL hydrogels were captured over 24 hours. Bright field images (40X) of the 
hydrogels are included at the top of each column for reference. Overlaid white lines represent 





Figure 4.2. Fluorescence intensity of FITC-dextran diffusion into HA-COL gels.  
Fluorescence intensities of 3, 70, and 500 kDa FITC-dextran probes were quantified at the x 
coordinates representing 200 μm (top), 500 μm (middle) or 1000 μm (bottom) from the gel edge 
and normalized to the surrounding liquid medium at several time points over 24 hours. 
Fluorescence intensity values were obtained by analyzing the micrographs such as those 
shown in Figure 1 using NIH ImageJ. The data shown are the average gray value of all pixels 






Figure 4.3. Encapsulated canine islet viability over three weeks.  
Viability of canine islets was measured at 3, 7, 14, and 21 days after encapsulation in gel with 
comparison to unencapsulated controls. Values shown are the mean viable fraction of individual 
islets for each group and time point from two combined donors. Significant differences are 








Figure 4.4. Encapsulated canine islet morphology.  
Representative micrographs (40X) were taken of encapsulated and control canine islets stained 
with dithizone at 3 and 21 days for morphological evaluation. Dithizone, red color, indicates the 
presence of insulin, and thus identifies healthy beta cells. Islets the expected appearance of 
smooth, rounded edges. In the control group at day 21, however, single cells were seen 
sloughing off from the islets, which was not observed in the encapsulated islet groups. The 







Figure 4.5. Glucose stimulated insulin secretion of encapsulated islets. 
Stimulation indices (ratio of high glucose insulin secretion to low glucose secretion) were 
measured at day 3, 7, 14, 21, and 28 in vitro for encapsulated islets in HA-COL and Alginate-
RGD hydrogels and for unencapsulated controls.  The stimulation index for control cells in 
media did not change significantly over time, also was true for islet encapsulated in HA-COL 
and alginate. (N=3 donor animals). (p<0.05). Incubation periods were 90 minutes for both low 







Figure 4.6. Photographs of the surgical procedure for transplantation of islets 
encapsulated in HA-COL hydrogel.  
Islets were encapsulated and transplanted into the rat omentum following a novel three step 
protocol. The omentum was first exteriorized and a base layer of gel applied and allowed to 
cross-link (A). Islets, suspended in a HA-COL precursor solution, were applied along large 
blood vessels for optimum nutrient exchange and the gel solution was allowed to solidify (B). 
The omentum was then rolled up and sutured to the stomach wall to minimize disturbance of 







Figure 4.7. Blood glucose levels of control animals.  
Non-encapsulated rat islet recipients (black diamonds, N=2) achieved normoglycemia initially, 
but by 11 days returned to a diabetic state after apparent allo-rejection of the transplanted 
tissue. Diabetic animals receiving sham surgery (open circles, N=3) without islets were 
hyperglycemic throughout the entire study period. For comparison, blood glucose levels of 







Figure 4.8. Hematoxylin and eosin staining of the omenta of unencapsulated islet 
transplant controls.  
H&E stained section of a typical healthy, untreated rat omentum, shown for comparison (A) 
(scale = 0.5 mm; magnification = 40X). Omentum of rat transplanted with unencapsulated islets, 
explanted 11 days post-transplant after blood glucose levels indicated graft rejection had 
occurred (B) (scale = 0.5 mm; magnification = 40X). Higher magnification of the center image 
(white square frame) showing significant lymphocyte infiltration in the region (C) (scale = 150 







Figure 4.9. Transplantation of islets in hydrogel. 
Average non-fasting blood glucose levels of 4 diabetic rats transplanted with islets 
encapsulated in HA-COL hydrogel over 1 year. “Day 0” marks the day of the islet transplant 
surgery. Values to the left of “day 0” were taken prior to transplant in order to confirm a diabetic 
state. All animals showed normal blood glucose levels at sacrifice. Data points beyond 40 






Figure 4.10. Hematoxylin and eosin staining of encapsulated islet transplants. 
Micrographs (200X) of H&E stained sections from the explanted graft showed intact hydrogel 
and very little or no fibrosis at the gel/tissue interface, indicated with black arrows. Tissues were 
explanted from rats that received encapsulated islet transplants at 40 (left), 52 (middle), and 64 
(right) weeks post-transplant. The large open spaces around the explanted hydrogel material 
were due to changes in the gel’s physical properties during paraffin embedding because of its 







Figure 4.11. Immunohistochemistry of explanted islet graft.  
Islets within the recovered graft displayed strong staining for the three major islet cell types – 
beta, alpha, and delta. Insulin is shown in green, glucagon in red, and somatostatin in blue (A). 
Histogram of cell composition of islets found in explanted tissue (N=70 islet sections) showing 






CHAPTER 5: A Novel and Versatile Method for Producing 
Hydrogel Microspheres for Islet and Cell Encapsulation§  
 
Abstract 
Cell encapsulation, while predominantly associated with islet transplantation, is a rapidly 
expanding field with broad potential utility in stem cell therapies and tissue engineering 
research. Sodium alginate has dominated this space due to its easy preparation as 
injectable hydrogel microspheres, but has been historically fraught with poor performance 
in vivo. Furthermore, more advanced hydrogel biomaterials are beginning to emerge 
including hyaluronic acid (HA), chitosan, and functionalized polymers that offer improved 
chemical and mechanical performance. Methods for formulating these advanced 
materials as convenient microspheres are wholly absent, largely due to their typically slow 
gelation kinetics. Thus, we have developed a novel method to produce hydrogel 
microspheres compatible with this class of materials. In this study, microspheres were 
produced using both an HA-based hydrogel and a standard photo-cross-linked 
polyethylene glycol diacrylated (PEGDA) hydrogel, and then characterized to determine 
basic physical and chemical properties. HA and PEGDA spheres possessed markedly 
different properties, demonstrating the versatility of this method, and both were well 
tolerated in vivo in a two-week rodent implantation model. 
  
                                            
§ In preparation as Harrington, S., Ramachandran, K., Stehno-Bittel, L. “A Novel and Versatile 
Method for Producing Hydrogel Microspheres for Islet and Cell Encapsulation,” for 





The concept of cell encapsulation was first popularized in 1980 by Lim and Sun, who 
showed that islets embedded in alginate hydrogel microspheres could reverse diabetes 
in rats without the need for immunosuppression, albeit for a only a few weeks. 47 This 
initial success, however, was followed by a flurry of research aimed at better 
understanding and improving this process. 42,49,59,164–176 Though great progress has been 
made, alginate microspheres have notoriously suffered from issues with long-term 
biocompatibility. 48,51,52,54–56 Despite these issues, alginate has persisted as the clear 
material of choice for islet encapsulation on account of its unique, near instantaneous 
cross-linking kinetics, enabling straightforward and nontoxic fabrication of convenient, 
injectable microspheres. Conversely, other hydrogels typically can only be prepared as 
bulk, macroscopic structures due to comparatively slower cross-linking rates. Some 
protocols have been developed for producing microspheres using alternative hydrogels 
such as agarose, chitosan, or hyaluronic acid (HA), but are based on oil-emulsions and 
are unattractive for cell encapsulation and transplantation due to harsh conditions and 
poor process control.97,177,178 
 
Cell encapsulation strategies are gaining attention for other applications as well, including 
improved stem-cell delivery and three-dimensional (3D) tissue culture. In 2016, Landazuri 
el al. demonstrated that microencapsulated mesenchymal stem cells (MSCs) dramatically 
enhanced paracrine-mediated healing in a murine hind-limb injury model, showing 
increased survival and pro-angiogenic activity compared to unencapsulated MSCs. 179 




has become a powerful tool for tissue engineering research in vitro. 180 For example, 
Rockwood et al. demonstrated that increasing the stiffness of the encapsulating matrix 
directed MSC differentiation toward a more osteogenic path versus a chondrogenic path 
for softer materials. 181 In another study, rat neuronal cells cultured in a 3D collagen 
hydrogel showed better survival and behaved more like native neuronal networks 
compared to cells grown in 2D on the same material. 182 
 
As applications of cell encapsulation continue to grow in number and sophistication, the 
ability to fabricate convenient, injectable, biocompatible microspheres using advanced 
biomaterials would be decidedly useful. Here, a novel method is described for producing 
hydrogel microspheres, termed core-shell spherification. This method was strategically 
designed for use with hydrogels with much slower gelation rates compared to alginate, 
thus enabling the production of microspheres with a variety of chemical, physical, and 
bioactive properties. Furthermore, the method was developed for use with standard, 
GMP-ready equipment (“good manufacturing practice” e.g. closed, sterile environment, 
tight process controls, material certificates for all parts) to better facilitate accessibility, 
scale, and regulatory compliance. 
  
To demonstrate the versatility of this new encapsulation procedure, we tested two 
different slow-gelation hydrogels, composed of either HA or polyethylene glycol 
diacrylated (PEGDA), and compared their properties with and without islets.  In addition, 






Isolation, Assessment and Culture of Canine Islets 
Canine islets were isolated from pancreas donated locally from euthanized donors as 
described in Chapter 3 of this dissertation. Isolated islets were converted to islet 
equivalents, or “IEQ”, for quantification purposes and evaluated for purity via dithizone 
staining. 23 Islets with a purity of < 60% were not used for the following studies. Canine 
islets were cultured in CMRL 1066 supplemented with 10% fetal bovine serum, 2 mM 
glutamine, and an antibiotic-antimycotic at 37 °C and 5% CO2.  
 
Cytotoxicity of Calcium and Hydrogel Precursor to Canine Islets 
Canine islets were exposed to solutions containing either 100 mM or 200 mM calcium 
chloride, 10 mM HEPES buffer, (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 
and 20% PEGDA, MW 3,400 (Laysan Bio, Inc.) for 5, 10, or 15 minutes. A group was also 
tested that contained 100 mM calcium chloride without the PEGDA component to 
evaluate the effect of calcium alone. Islets were suspended at approximately 5,000 
IEQ/mL in the test solutions to reflect the high cell loading density associated with the 
encapsulation process. At the end of the test periods, the islets were washed twice with 
supplemented CMRL 1066 islet media and then incubated at 37 °C and 5% CO2 for three 
hours prior to assessment.  
 
Islet cytotoxicity was evaluated via propidium iodine staining and fluorescence 
microscopy. Fluorescence micrographs were captured with a Cytation 5 Imaging Multi-




calculating the ratio of red (dead) pixels to total islet pixels using Adobe Photoshop as 
described previously. 19 Twenty-five individual islets were analyzed per group. Results are 
reported as the average viable cell fraction and normalized to islets from the matched, 
untreated controls.  
 
Cytotoxicity of Ultraviolet Light Exposure and Photoinitiator to Canine Islets 
Canine islets were suspended in Dulbecco’s phosphate buffered saline (DPBS) 
containing 0, 0.025, or 0.05% (w.v) Irgacure 2959. Islets were loaded into wells of a 24-
well plate and irradiated with long-wave ultraviolet (UV) light for 3, 5, or 10 minutes. 
Approximately 50 islets were in each test well in two mL of DPBS. A PortaRay 400 UV 
lamp was used for irradiation in low-power mode at a distance of 6”, which corresponds 
to approximately 40 mW/cm2 according to manufacturer data (Uvitron International). After 
exposure, islets were washed twice with supplemented CMRL 1066 islet media and then 
incubated at 37 °C and 5% CO2 for three hours prior to assessment. Cell death was 
evaluated via propidium iodide staining and quantified as described in the previous 
section. 
 
Fabrication of Hyaluronic Acid Hydrogel Microspheres 
Hyaluronic acid hydrogel precursor was prepared by dissolving a thiolated HA (HyStem, 
Biotime Inc) at 1.2% (w/w) in a custom buffer containing 100 mM calcium chloride, 15 mM 
HEPES, and 20% (w/w) OptiPrep (CosmoBioUSA, Inc) as a density modification agent. 
The viscosity of the precursor solution was measured with a Cannon-Manning Semi-Micro 




extruded via automated droplet generator into a stirred bath of 0.15% (w/v) sodium 
alginate (Protanal LF 10/60, FMC Corp.) containing 300 mM mannitol, 0.1% Tween 20, 
0.4% (w/v) PEGDA 3,400 (Laysan Bio, Inc), and adjusted to pH 7.6 using a custom 15 
mM HEPES buffer. The droplet generation system utilized was a Buchi 395-Pro 
Encapsulator (Buchi Corporation, Newcastle, DE) equipped with an air jet nozzle system 
and a 400-micron diameter inner fluid nozzle within a 1.5 mm concentric air nozzle. The 
precursor solution was extruded at 1.5 mL/min with an airflow rate of 2.2 L/min using 
compressed nitrogen as the air source. Core-shell constructs formed upon contact with 
the bath that contained the hydrogel precursor in the spherical core. The constructs were 
stirred gently for 5 minutes in the original bath solution, then the bath was diluted by half 
with DPBS, which reduced the solution pH to 7.4. The bath was stirred for an additional 
30 minutes to continue cross-linking of the HA precursor within the core. The core-shell 
constructs were next rinsed in a 25 mM citrate buffer in DPBS for 5 minutes under mild 
stirring to dissolve the alginate shells, collected using a steel mesh screen and suspended 
in DPBS. A second rinse in 50 mM citrate for 5 minutes was performed to ensure complete 
dissolution and removal of the alginate shell. Final HA microspheres were stored in 
DPBS. A general schematic of the hydrogel microsphere fabrication process, termed 
core-shell spherification, is provided for clarity in Figure 5.1.  
 
Fabrication of PEGDA Hydrogel Microspheres 
PEGDA hydrogel precursor solution was prepared by dissolving PEGDA 3,400 and 
20,000 (Laysan Bio, Inc.) at 18% and 12% (w/w), respectively, in a custom buffer 




The solution was filtered using a 0.22-micron syringe filter and the viscosity was 
measured as described above. The precursor was extruded as described above into a 
stirred alginate bath containing 0.15% (w/v) sodium alginate (Protanal LF 10/60, FMC 
Corp.), 300 mM mannitol, 0.1% Tween 20, 0.025% (w/v) Irgacure 2959, and adjusted to 
pH 7.4 using a custom 15 mM HEPES buffer to form core-shell constructs. All solutions 
for PEGDA microsphere fabrication were prepared in water degassed by sonication to 
eliminate excess oxygen, which can inhibit photo-cross-linking. 183–186 The bath containing 
the core-shell constructs was irradiated with long-wave UV light such that the irradiance 
at the center of the bath was approximately 40 mW/cm2 (PortaRay 400, Uvitron 
International). Irradiation was applied at all times during extrusion of the precursor 
solution and for one minute after extrusion to ensure complete cross-linking of all core-
shell constructs. Constructs were processed further as described above to dissolve the 
alginate shells.  
 
Encapsulation of Canine Islets in PEGDA Microspheres 
The PEGDA precursor solution was prepared as described above at 1.1X concentration 
(i.e. 110 mM calcium, 33% total PEGDA, etc) and later combined with a slurry of canine 
islets in CMRL 1066 media at volumetric ratio of 10:1 just prior to extrusion. Core-shell 
constructs were generated and cross-linked as described above using a fully enclosed 
sterile reaction vessel designed specifically for the Buchi 395-Pro Encapsulator to 
maintain tissue sterility. Alginate shells were removed as described above with the 
exception that Hank’s Balanced Salt Solution (HBSS) was used in place of DPBS for all 




media and incubated at 37 °C and 5% CO2. Media was exchanged completely one hour 
after fabrication.  
 
Physical Properties and Size Distribution of Hydrogel Microspheres  
Representative samples of the hydrogel microspheres were dispensed into a 24-well 
plate and imaged using a Cytation 5 Imaging Multi-Mode Reader (Biotek Instruments, 
Inc). Diameters of 100 individual microspheres were measured to determine the average 
microsphere diameter and size distribution for each microsphere type.  
 
Hydrogel microspheres were further characterized by determination of the swelling ratio, 
“Q”, for each microsphere type, which is the ratio of the swollen hydrated mass to the dry 
mass. Several hundred microspheres were placed on a Kimwipe to remove excess 
surface moisture and then weighed on a pre-weighed watch glass. The spheres were 
then dried overnight at 60 °C and reweighed to obtain the dry mass.  
 
Diffusion Characteristics of Microspheres 
Hydrogel microspheres were incubated overnight in 0.1 mg/mL solutions of FITC-labelled 
dextrans in DPBS with average molecular weights of 10, 40, 70, and 500 kDa (Molecular 
Probes). Microspheres were then rinsed with DPBS and imaged via fluorescence 
confocal microscopy to monitor efflux of the probes (Olympus Fluoview 300). 
Fluorescence micrographs were captured between three and 150 minutes after removing 





Implantation of Hydrogel Microspheres into Rat Omentum 
Healthy Sprague-Dawley rats were used to evaluate the safety and initial biocompatibility 
of the microspheres produced by the core-shell spherification method (N=2 per 
microsphere type). Microspheres were implanted to the omentum following the protocol 
described in Chapter 4 of this dissertation with the exception of the delivery of the 
biomaterial. For these surgeries, microspheres were delivered via syringe as a 
suspension in DPBS. Approximately 1 mL of loosely packed microspheres were 
deposited directly to the omentum of the rat, which was subsequently sutured to the 
stomach wall to hold the microspheres in place for easier retrieval. Photographs of the 
surgery can be seen in Figure 5.2 for additional clarity. Rats were monitored and scored 
for pain and activity levels for the 10 days following implantation of the microspheres.  
 
Necropsy and Histological Evaluation of Implanted Microspheres 
Rats were sacrificed 14 days after implantation for evaluation of the implantation site for 
signs of gross inflammation and tissue abnormalities. Tissue samples were collected and 
preserved in neutral buffered formalin, embedded in paraffin and sectioned at 7 micron 
thicknesses. Sections were stained with H&E and evaluated microscopically. Color 




Cytotoxicity data were analyzed for significant differences by two-way ANOVA. Pairwise 




associated with islets, cytotoxicity data were in violation of the normality and equal 
variance assumptions. For this reason, pairwise comparisons were denoted as significant 
at p < 0.05 or p < 0.001 for added clarity in interpreting the results.  
 
Results 
Islet Cytotoxicity Studies 
Critical components of the core-shell spherification process were evaluated to identify 
thresholds for cytotoxicity to islets, specifically high levels of calcium ion and high intensity 
UV irradiation. Figure 5.3 depicts the effects of calcium concentration and exposure time 
to canine islets with or without the PEGDA precursor component. At the shortest 
measured exposure time of 5 minutes, no significant difference in cytotoxicity was 
observed for any group, which were 200 mM calcium, and 100 mM calcium with and 
without PEGDA. All groups were above 97.5% viability compared to controls. However, 
a strongly significant drop in viability was seen in the 200 mM calcium group at each 
subsequent time point compared to the 5-minute measurement. Further, viability in the 
200 mM group was significantly lower than the two 100 mM groups at both 10 and 15 
minutes. No differences were observed in either of the 100 mM groups through 10 
minutes. However, at 15 minutes, the 100 mM group containing PEGDA showed a 
significant decrease in viability compared to the 5- and 10-minute time points and to the 
100 mM group without PEGDA at 15 minutes. Interestingly, no significant change in 
viability was observed at any time point within the 100 mM group without PEGDA, which 





The effects of photoinitiator concentration and UV light exposure time are shown in 
Figure 5.4. Canine islets were subjected to ~40 mW/cm2 long-wave UV exposure for 3, 
5 and 10 minutes at Irgacure 2959 concentrations of 0, 0.025, and 0.05% (w/v) and 
evaluated for cytotoxicity. Little cytotoxicity was observed in either of the groups 
containing Irgacure at any time point, as no significant difference in viability was detected 
within groups across the three time points. Interestingly, the group containing no 
photoinitiator showed the highest degree of cytotoxicity of all groups. Viability in the 0% 
group was significantly lower at 5 minutes and 10 minutes with respect to the 3-minute 
exposure time. Further, the 0% group was significantly less viable at 5 and 10 minutes 
compared to both Irgacure groups. The only significant difference detected between the 
0.025 and 0.05% groups was at 10 minutes with viable cell fractions of 94.5 and 87.2%, 
respectively.  
 
Physical Properties and Size Distribution of Hydrogel Microspheres 
Hydrogel microspheres were fabricated using a novel core-shell spherification method. 
Figure 5.5 depicts the core-shell constructs just after fabrication and prior to crosslinking. 
Alginate shells were characterized by a concentric ring-link morphology, and core 
diameters were typically between 600-800 µm. Microspheres composed of HA or PEGDA 
were characterized to determine size distribution and swelling ratio. Table 5.1 provides 
some physical properties of the hydrogel formulations before and after cross-linking, as 
well as the average diameter and diameter range. HA microspheres were markedly 
smaller than PEGDA microspheres despite having been fabricated using the same 




in total polymer mass fraction after cross-linking while PEGDA microspheres dramatically 
decreased from the starting levels. However, PEGDA gels still exhibited a much lower 
swelling ratio “Q”, indicating a more compact overall hydrogel. The incorporation of islets 
into the PEGDA microspheres resulted in a slightly larger average diameter, but, 
interestingly, also resulted in a narrower diameter range. This is illustrated further in 
Figure 5.6, which contains scatter plots depicting the diameters of 100 representative 
microspheres composed of HA, PEGDA, or PEGDA with islets. Indeed, PEGDA spheres 
with islets had a much tighter band compared to empty PEGDA microspheres, which 
exhibited relatively broad size distribution and comparatively low clustering compared to 
the other two groups. HA microspheres were much smaller in size than both PEGDA 
groups, and had a relatively small size distribution, similar to the PEGDA-islet group.  
 
Diffusion Characteristics of Microspheres 
Figure 5.7 illustrates diffusion characteristics of the HA and PEGDA hydrogel 
microspheres fabricated by the core-shell spherification method. Microspheres were 
incubated in fluorescent probes of varying molecular weight, rinsed, and then examined 
by confocal microscopy to characterize the extent of diffusion into the microspheres and 
monitor efflux of the probes. Fluorescence micrographs were taken at the equator of the 
microspheres at 3, 10, 30, and 150 minutes after rinsing the spheres in blank DPBS. The 
HA microspheres (Figure 5.7A) showed strong fluorescence signal from all probes, 
indicating that all were able to penetrate the gel matrix. Signal from the 10 kDa probe 
diminished quickly compared to the larger probes, and was near equilibrium at the 30-




the 40 and 70 kDa probes was stronger within the area of the microsphere compared to 
the surrounding medium at the latest time point of 150 minutes, which was not observed 
with the other two probes, suggesting that the probe had either not completely diffused 
out of the sphere or had become adsorbed to the matrix due to favorable thermodynamic 
interactions. PEGDA microspheres (Figure 5.7B) displayed comparatively weak 
fluorescence to the HA spheres. While strong signal was detected from the 10 kDA probe 
in the PEGDA group, efflux of the probe appeared less rapid than in the HA group. The 
40 kDa probe displayed some positive fluorescence from within the PEGDA spheres, but 
was much less extensive than in the HA group. The 70 kDa and 500 kDa probes did not 
appear to penetrate to any appreciable extent as indicated by the very weak, granular 
fluorescence signal. Interestingly, fluorescence distribution between the microsphere and 
surrounding medium appeared to reach near or complete equilibrium in the in these two 
groups at the 30-minute time point, which was not seen in the HA gels, a possible 
indication that the probes had weakly adsorbed to the surface of, but not penetrated into, 
the microsphere matrix. 
 
Encapsulation of Canine Islets in PEGDA Microspheres 
Canine islets were encapsulated to demonstrate the compatibility of the core-shell 
spherification process for cell encapsulation. Figure 5.8 shows representative images of 
canine islets encapsulated in PEGDA microspheres after 14 days in culture. Islets 
displayed strong red dithizone staining, which confirms the presence of insulin and 




edges, another indication of viability. Unstained tissue is exocrine pancreas tissue that 
was carried over from the original islet isolation process.  
 
Evaluation of Safety and Initial Biocompatibility of Microspheres 
HA or PEGDA microspheres were implanted into the omenta of healthy Sprague-Dawley 
rats (N=2 per group) to evaluated the safety and biocompatibility of microspheres 
produced using the core-shell spherification method. Animals were monitored for 10 days 
post-op for signs of pain and reduced activity, which were scored daily between 0 and 3, 
with 0 being normal and 3 being severe abnormalities. All pain and activity scores were 
0 for all 10 days in all four rats. No observations of porphyria, poor grooming, skin 
discoloration, pica, weight loss, self-mutilation or decreased activity were made in any of 
the animals. Necropsies were done after 14 days and no signs of acute inflammation, 
pus, excess fluid, or tissue abnormalities were observed throughout the abdominal cavity, 
though some tissue adhesions were identified, particularly where the omentum was 
sutured to the stomach wall. Photographs of the implantation sites during surgery are 
provided in Figure 5.2, for reference. Both HA and PEGDA microspheres were found 
intact in the omentum, and were visually translucent, and appeared to be surrounded by 
a very thin film-like layer, which can be seen in Figure 5.9. In one of the PEGDA implanted 
rats, microspheres were found adhered to the surface of the liver, evidently having 
escaped from the omental pouch after implantation (Figure 5.9B). Hematoxylin and eosin 
staining of the explanted tissues is shown in Figure 5.10 for both microsphere groups. 
Microspheres generally appeared intact, as was expected from the necropsy 




It was common to find microspheres possessing a thin layer of cells around their 
perimeters, often two or three cells thick, and all were devoid of cells in the interior. As 
microspheres were randomly distributed into the omentum, some single microspheres 
were isolated, surrounded by normal omental tissue (Figure 5.10A-D), while some were 
surrounded by a large population of what appeared to be primarily fibroblasts and some 
lymphocytes, characterized by either an elongated or near absent cytoplasm, respectively 
(Figure 5.10EF). These large populations of cells were typically associated with large 
clusters of microspheres in close proximity to one another, where isolated spheres tended 
to have very few “non-omental” cells nearby. In many cases, newly formed blood vessels 
were identified in the tissues near the microspheres, examples of which can be seen in 
Figure 5.10EF denoted by white arrows.  
  
Discussion 
We have developed and evaluated a new method for fabricating hydrogel microspheres 
for cell encapsulation and delivery. Current methods for cell micro-encapsulation are 
mostly based on alginate spheres 42,45,47,49,56,175,187–190, and others utilize harsh oil-
emulsion techniques. 97,178,191,192 Alternatively, our method, termed core-shell 
spherification, could be used for a wide variety of hydrogel materials and is compatible 
with standard, commercially available and GMP-ready equipment and requires minimally 
cytotoxic conditions. Though primarily considered for islet or islet-like cell transplantation 
for diabetes, cell microencapsulation has also shown promise as a useful tool for stem-
cell therapies and in vitro 3D tissue culture systems for drug development and disease 




sophistication, our novel method for producing convenient cell-laden hydrogel 
microspheres from a variety of biomaterials could be of broad potential value for these 
applications. 
 
Because islets do not replicate in vitro, low cytotoxicity is a critical feature for islet 
encapsulation strategies. Thus, we evaluated some of the key enabling components of 
the core-shell spherification method for cytotoxic effects using canine islets. Specifically, 
high levels of calcium are required for core-shell construct formation, particularly at small 
droplet sizes, or exposure to high intensity UV light is required for effective crosslinking 
of photo-initiated hydrogels such as PEGDA. Not surprisingly, 200 mM calcium was very 
quickly and significantly cytotoxic to islets. However, we found that islets tolerated 100 
mM calcium very well even in a highly concentrated and viscous PEGDA solutions for at 
least 10 minutes. Furthermore, when PEGDA was not present, canine islets in 100 mM 
calcium showed no significant reduction in viability for up to 15 minutes.  
 
Exposure to 40 mW/cm2 long-wave (~365 nm) UV light was, overall, minimally cytotoxic 
to canine islets for at least 10 minutes. Unexpectedly, the group without photoinitiator, 
Irgacure 2959, displayed the most cell death after UV exposure. This is in contrast to 
results reported in several other studies that examined toxicity of the same photoinitiator. 
195–198 However, these studies involved much lower UV intensity, between 4-10 mW/cm2, 
and the photoinitiator concentration used herein were comparatively low. Thus, it appears 
that, at least at very high UV intensity, the photoinitiator may actually offer a protective 




a concentration dependent increase in cytotoxicity was still observed in the groups 
containing Irgacure, which is in agreement with the studies cited above. Further, the UV 
irradiation conditions utilized herein for microsphere production (40 mW/cm2, 0.025% 
Irgacure) produced no significant decrease in islet viability for at least 10 minutes, and 
had a minimum viable cell fraction of 94.5% compared to controls. Advantageously, a 
maximum capacity production run with the present encapsulation equipment required a 
UV exposure time of about six minutes.   
 
Microsphere diameter is an important factor for downstream applications of encapsulated 
cells, particularly islet transplantation. 142 Because a sizeable number of cells are required 
to reverse diabetes (e.g. ~10,000 IEQ/kg) 63,67, microsphere volume becomes a major 
concern. Furthermore, smaller spheres are more convenient to handle in vitro and are 
easier to deliver via syringe for transplantation. Despite being fabricated under the same 
conditions, the HA and PEGDA microspheres described in this study were vastly different 
in size, with average diameters of 637 and 904 µm, respectively. These diameters 
correspond to an average microsphere volume of 135 and 386 nanoliters, roughly a 3-
fold difference in total volume per sphere.  
 
The difference in size between the HA and PEGDA is most likely a result of the swelling 
behavior of the two hydrogel materials. Hydrogel swelling is governed by a number of 
variables, but is strongly related to the overall concentration of polymer and the density 
of cross-links within the gel, with changes in either of these two having opposite effects 




the gel matrix, while an increase in polymer concentration tends to promote swelling by 
increasing the affinity of the matrix to bind water. A major difference between the HA and 
PEGDA gels was the initial polymer concentration of the hydrogel precursor solutions, 
which were 1.2% and 30% by mass, respectively. Thus, a high degree of post-fabrication 
swelling in the PEGDA spheres is likely a primary factor contributing to their much larger 
size. This is corroborated by the massive reduction in polymer mass fraction measured 
for the final constructs, which was only 5.8%, though it is also likely that some of this 
decrease in mass fraction was due to diffusion of some of the precursor out of the alginate 
shell before cross-linking was complete. Conversely, the final mass fraction of the HA 
spheres was triple the initial value (3.6% vs 1.2%). This is likely due in part to the 
incorporation of the cross-linking molecule (PEGDA 3,400) as it diffused into the core 
through the alginate shell and reacted with the HA polymers. However, it is also possible 
that as a result of the very low initial polymer concentration, the HA spheres may have 
contracted, as cross-link density continued to increase after the initial core-shell 
constructs were formed. Though not included in this chapter, evidence of this HA gel 
contraction is provided in Appendix B of this dissertation.  
 
Diffusion properties were also considerably different between the HA and PEGDA 
microspheres. HA microspheres were highly permeable to dextran probes up to 500 kDa 
in size, while PEGDA spheres appeared to severely limit diffusion of dextrans above 70 
kDa. Indeed, the degree of gel swelling is likely a key contributor these phenomena. The 
swelling ratio “Q” (the ratio of the equilibrium hydrated mass to the dry mass of the gel), 




can affect this property. 156,200 The HA and PEGDA microspheres in this study had Q 
values of 27.7 and 17.3, respectively. Durst et al. published an excellent report in 2011 
correlating the swelling ratio of a number of PEGDA hydrogel formulations to their 
average pore size. In this report, gels with similar Q values to those reported here (26.4 
and 17.7) corresponded to an average pore size of 17.2 and 11.7 nm, respectively. 
Further, the hydrodynamic radius of a 500 kDa dextran has been reported as 15.6 nm. 46 
Thus, the permeability of the 500 kDa dextran into the HA microspheres is well in line with 
other observations, at least in terms of its swelling ratio.  
 
Results of the diffusion studies were less straightforward for the PEGDA microspheres 
than for HA. Of particular note was the marked attenuation of fluorescence signal near 
the center of the sphere for both the 10 kDa and 40 kDa probes, and the near absent 
penetration of the 70 kDa probe. The hydrodynamic radius of a 40 kDa and 70 kDa 
dextrans are reported to be 4.78 and 6.49 nm, respectively. 46 Thus, given the Q value for 
the PEGDA gels and corresponding estimated mesh size, penetration of these probes 
would be expected, though it should be reiterated that mesh size is dictated by many 
factors other than swelling ratio. A likely explanation for the unexpected fluorescence 
patterns in the PEGDA gels two-fold. First, as mentioned above, it is possible and even 
likely that some of the PEGDA molecules diffused out of the alginate shell before cross-
linking was complete. This phenomenon would, in theory, produce a polymer 
concentration gradient within the core and therefore in the resulting gel microsphere once 
cross-linked. This could in turn produce a permeability gradient such that diffusivity 




polymer density of the PEGDA compared to HA microspheres (5.8% vs. 3.6% mass 
fraction) could have led to optical effects during imaging. Because the constructs are 
spherical, the amount of material light must penetrate increases toward the center of the 
construct, potentially leading to a shadow-like artifact, which would be more pronounced 
in the more concentrated PEGDA microspheres. Furthermore, a “shadow” artifact such 
as this would in theory be exacerbated if the spheres indeed possessed a polymer density 
gradient as discussed above. However, such hypotheses would require additional 
experimentation to confirm. Overall, it is clear that the PEGDA microspheres were far less 
permeable compared to the HA microspheres.   
 
Finally, hydrogel microspheres intended for cell transplantation and immunoprotection 
must accomplish the following three things: 1) induce no negative effects to the host 
organism, 2) prevent the infiltration of host lymphocytes into the encapsulating matrix, 
and 3) avoid severe foreign body reaction resulting in an avascular fibrous capsule around 
the microsphere, which would lead to necrosis of the encapsulated cells. To explore these 
points, HA and PEGDA microspheres were implanted into healthy rats for a two-week 
period. All animals displayed no classical signs of pain or reduced activity 201 after 
implantation of the spheres even despite undergoing open abdominal surgery. 
Necropsies showed no internal signs of tissue abnormality or necrosis, providing further 
confirmation that the presence of the microspheres was well tolerated by the host. 
Microspheres appeared intact and were translucent in appearance. Histological analysis 
of the implantation site revealed a thin layer of cells around many of the microspheres, 




several regions in which spheres were surrounded by a dense population of cells primarily 
consisting of fibroblasts, and no cells appeared to have penetrated into the microspheres. 
Evidence of neovascularization was also identified in these more cellular regions. 
Interestingly, the incidence of fibroblast proliferation appeared to be largely associated 
with regions containing large numbers of spheres in close proximity to each other. These 
observations are indicative of an early stage/mild foreign body reaction, which is expected 
in response to the implantation of a biomaterial. 202 However, signs of advanced stage 
foreign body reactions associated with fibrous encapsulation are typically not observable 
after only two weeks, and are initiated by a number of physiological and material-based 
factors. 203–206 Thus, more comprehensive and longer-term in vivo studies will be required 
to fully characterize the extent of foreign body responses elicited by the HA and PEGDA 
microspheres.  
 
In conclusion, the novel method presented herein for producing hydrogel microspheres 
is a promising new tool for cell transplantation and tissue engineering research. This 
method, termed core-shell spherification, could be applied to a wide variety of hydrogel 
materials, thereby enabling broad control of microsphere properties for application 
specific purposes. In the present study, microspheres were produced with markedly 
different size, structural, and mass transport properties with minimal modifications to the 
fabrication protocol. Furthermore, microspheres evoked no negative effects in vivo and 
appeared to be well tolerated, though long-term biocompatibility studies are needed. 














Figure 5.1. Schematic of core-shell spherification method. 
Hydrogel precursor solution is prepared with calcium chloride and mixed with cells. The 
precursor is then extruded into an alginate bath to generate spherical core-shell constructs in 
which the hydrogel precursor and cells are entrapped within the shell (1). The precursor is 
cross-linked by diffusion of a small cross-linker through the shell, or by irradiation with activating 
UV light (2). The alginate shell is finally dissolved with citrate, leaving only the cross-linked 






Figure 5.2. Photographs of microsphere implantation surgery. 
Hydrogel microspheres were implanted into healthy Sprague-Dawley rats to evaluate initial 
biocompatability and safety. A small midline incision was made in the abdomen and the 
stomach and greater omentum were exteriorized. Microspheres were deposited via syrine in a 
DPBS suspension on the surface of the omentum (A). The omentum was subsequently sutured 
to the stomach wall to hold the microspheres in place for easier retrieval (B). The stomach and 








Figure 5.3. Cytotoxicity of calcium exposure in hydrogel precursor. 
Canine islets were exposed to elevated calcium levels similar to those encountered during 
microsphere fabrication and evaluated for cytotoxicity at 5, 10, and 15 minutes. A group without 
the PEGDA precursor (100 mM No PEG) was also evaluated to better illustrate the effects of 
calcium alone. Cytotoxicity was evaluated using propidium iodide fluorescence staining and 
results are shown as the average viable cell fraction of 25 individually analyzed islets. Data 
were normalized to untreated controls.  Significant differences are denoted either by an * (p < 







Figure 5.4. Cytotoxicity of photoinitiator and UV exposure. 
Canine islets were exposed to long-wave UV light in DPBS solutions containing 0, 0.025, or 
0.05% Irgacure 2959 to evaluate the cytotoxicity of the photo-cross-linking process. Islets were 
irradiated at approximately 40 mW/cm2 for 3, 5, or 10 minutes. Cytotoxicity was evaluated using 
propidium iodide fluorescence staining and results are shown as the average viable cell fraction 
of 25 individually analyzed islets. Data were normalized to untreated controls.  Significant 








Figure 5.5. Example of core-shell constructs. 
Core-shell constructs had spherical cores and wide, diffuse alginate shells. Alginate shell had 
a concentric ring-like appearance. Core diameters of constructs produced with the current 







Figure 5.6. Size distribution of hydrogel microspheres. 
The diameters of a representative sample of 100 microspheres of each material type were 
measured and displayed in a scatter plot to visualize the size distribution. All microspheres were 
produced using a 450-micron air jet nozzle system under the same production parameters. The 







Figure 5.7. Diffusion of FITC-dextrans in hydrogel microspheres. 
Hydrogel microspheres were incubated for 24 hours in solutions containing FITC-dextrans of 
increasing molecular weight. After incubation, the FITC-dextran solutions were exchanged with 
blank DPBS and the microspheres were monitored via confocal microscopy for 150 minutes to 
visualize efflux of the dextran probes. Images of the HA (A) and PEGDA (B) microspheres 
captured at the sphere equator are displayed for each condition at 3, 10, 30, and 150-minute 






Figure 5.8. Canine islets encapsulated in PEGDA microspheres. 
Canine islets were encapsulated in PEGDA hydrogel microspheres and cultured for 14 
days to evaluate islet survival. Islets within the spheres were stained with dithizone, a 
common islet stain, which binds to insulin within the islets. Islets showed strong staining 
after two weeks in culture and possessed smooth, rounded edges, which are both signs 
of good islet health. Unstained tissue is remnant exocrine tissue that remained trapped 






Figure 5.9. Photographs of microspheres at necropsy. 
Healthy Sprague-Dawley rats were implanted with empty HA or PEGDA microspheres. 
Microspheres were deposited onto the greater omentum of the rat and sutured to the stomach 
wall. Necropsies were performed 14 days after implantation of HA (A) or PEGDA (B) 







Figure 5.10. H&E staining of microspheres explanted after 14 days.  
Implanted microspheres and surrounding tissues were recovered at 14 days and stained with 
H&E. Cellular deposition and host tissue response to HA (A,C,E) and PEGDA (B,D,F) 
microspheres were similar. In some regions, microspheres were identified surrounded by only 
thin layer of cells, often 2-3 cells thick (A-D), and were surrounded by normal, healthy omental 
tissue. In other regions, microspheres were surrounded by a dense population of cells, primarily 
fibroblasts, and newly formed blood vessels, which are denoted by white arrows (E,F). Scale 











CHAPTER 6: Conclusion 
 
Summary of Experimental Work 
Islet transplantation is approaching a point of saturation as a treatment for human type-1 
diabetes. Limited donor tissue and mandatory immunosuppression ultimately preclude 
the availability of this treatment to the overwhelming majority of diabetics. Therapies 
based on renewable, stem-cell-derived islet replacements, which are in need of 
substantial breakthroughs, are now the only foreseeable path toward mainstream 
application of this treatment in humans. Meanwhile, canine diabetes, which is strikingly 
similar to human diabetes and rapidly increasing in prevalence, is treated with outdated 
and marginally effective therapies. Despite an extensive history of islet transplantation 
research in canines for human application, it has never been seriously explored as a 
veterinary treatment option for diabetic pets and their owners. As such, the primary goal 
within this dissertation was to address the key challenges facing the translation of islet 
transplantation to veterinary medicine. As a corollary to this goal, I developed and 
patented a useful cell encapsulation technique applicable not just to canine islet 
transplantation, but to the broader field of cell therapy and regenerative medicine.  
 
The first and most obvious component needed for canine islet transplantation is a source 
of canine islets. In research, canine islet tissue was routinely sourced from laboratory 
animals with little regard to cost. However, when progressing from a laboratory setting to 
the clinic, the use of purpose-bred canines would be ethically and economically 




process of islet isolation under the deleterious conditions inherent to organ donation from 
canines previously euthanized at veterinary clinics or shelters, without the benefits of 
heart-beating organ procurement and negligible ischemia afforded in experimental 
research. Furthermore, studies were also targeted at optimizing process efficiency 
specifically for the canine pancreas, which varies tremendously in size depending on 
donor bodyweight. Of particular note, I demonstrated that roughly one third of the 
pancreas could be effectively discarded without significantly impacting islet yield, which 
led to commensurate savings in both processing time and material costs. Overall, this 
work led to a reliable, cost-efficient protocol for isolating transplant quality canine islets 
from ethically obtained donor pancreas, a critical step in bringing clinical islet 
transplantation to diabetic canines.  
 
Canine and human islet transplantation have a common enemy in the requirement of 
immunosuppression to prevent graft rejection. I address this problem in Chapters 4 and 
5 of my dissertation in the examination of more advanced biomaterials for islet 
encapsulation and delivery. Despite great improvement in standard alginate-based 
technologies, a new wave of smarter and more biomimetic materials are beginning to 
emerge as alternatives to alginate hydrogels for cell encapsulation. One such example, 
and the primary focus of my research, are hydrogels derived from hyaluronic acid (HA), 
a natural and abundant component of native extracellular matrix. HA hydrogels have been 
employed successfully in vivo in several previous studies 91–94,207, but never as an 
immunoprotective matrix for islet transplantation. Encouragingly, I demonstrated that a 




term immune rejection of transplanted allogeneic islets in rats, which remained cured of 
diabetes for the entire duration of the study. 
 
While effective in the laboratory, the surgical procedure used in the initial rat studies was 
invasive, required specialized training to properly prepare the islet-laden hydrogels in situ, 
and therefore unlikely to be adopted clinically. Thus, I began to explore techniques to 
fabricate injectable microspheres composed entirely of this promising HA hydrogel 
material. My primary objective with this project was to design a process that would easily 
translate into a commercial setting. So, I incorporated only readily accessible materials, 
and developed the procedure using standard commercial equipment designed for sterile 
operation and cGMP compliance.  As the new fabrication process started to take form, it 
became apparent that it was not limited the HA hydrogel, but potentially compatible with 
a wide variety of biomaterials and thereby a wide variety of applications. The second 
iteration of this new method was fabricating PEGDA microspheres on account of the well-
established biocompatibility and commercial availability of this material.  Ultimately, these 
studies led to a United States Patent covering the method, now termed core-shell 
spherification, which was officially issued in 2017.  
 
Future Directions 
Though a donor-based clinical program has far more room to grow in canine diabetes 
than in humans, the supply of islets will most likely fall exceedingly short of demand in 
veterinary medicine as well. Eventually, a stem-cell derived islet surrogate will be needed 




system will be crucial to ensure the safe delivery and long-term survival of these new 
cells. To this point, future application of this work will largely lie in the continued 
development of the core-shell spherification protocol. Initial in vivo studies were 
conducted, but a long-term evaluation both of microsphere biocompatibility and the fate 
of encapsulated islets/cells within will need to be completed. Furthermore, as 3D tissue 
culture is gaining popularity for both tissue engineering and disease modeling, the ability 
to microencapsulate cells within a broad variety of hydrogels could have great value 
outside of cell therapy as well.  
 
The conditions of the core-shell spherification method present some interesting 
opportunities for development, namely, the potential for producing gradiential 
microspheres or even liquid-core capsules. For example, in the case of the HA hydrogels, 
the cross-linking molecule diffuses inward from the surrounding bath. Presumably, given 
enough time, the cross-linker equilibrates within the core area and produces a uniform 
gel. However, the cross-linker used here, PEGDA, reacts relatively slowly with the HA 
polymers, causing gelation in 10-30 minutes, in general. Another cross-linker for this 
hydrogel, PEG-dimaleimide (PEGDMal), reacts much more rapidly, on the order of just 
several seconds. If PEGDMal were used instead of PEGDA, cross-linking would occur 
much more rapidly near the core-shell interface, and early termination of the reaction 
could enable generation of liquid-core capsules. In contrast, for photo-cross-linkable gels 
such as PEGDA, the opposite could be done by removing the photoinitiator from the 
surrounding bath or decreasing its concentration to induce a chemical gradient. In this 




resulting in hydrogel microspheres that decrease in stiffness and diffusivity toward the 
exterior of the gel. This type of microstructure could be useful to control degradation 
profiles in applications where permanent residence of the hydrogel is not desired, such 
as in stem-cell assisted wound healing. 179 Beyond these examples, incorporation of 
additional hydrogel materials into the method such as chitosan 87,96 or functionalized 
smart polymers 88,192 should be explored in future studies as well.  
 
In summary, this work has laid the groundwork necessary to expand the exciting option 
of islet transplantation to a growing population of diabetic dogs and their owners that have 
long awaited a better solution. Beyond this, the novel method for microencapsulation of 
cells developed in pursuit of this goal has potential as a versatile platform for a variety of 
applications in regenerative medicine. As cell therapies and 3D tissue culture continue to 
expand their role in medicine and research, tools for implementing these new strategies, 
including the method introduced herein, will be increasingly useful. In this light, the 
present approach of translating this new technology first into veterinary medicine could 
facilitate a shorter time to market with less overall risk, and potentially create a strategic 




APPENDIX A: Evaluation of a Simplified “ex vivo” Vascular 
Preservation Method of Canine Pancreas for Islet Isolation 
after Overnight Shipping 
 
The following data were presented in poster format at the National AALAS 2015 Annual 
Meeting in Phoenix Arizona under the title “Successful Islet Isolation from Canine 
Pancreas Procured Post-Circulatory Death and After Extended Cold Ischemia”. 
 
Introduction 
Diabetes mellitus is one of the most common endocrine disorders of dogs and cats and 
is characterized by a failure to adequately control blood glucose due to loss or dysfunction 
of pancreatic beta cells. Over 1 million dogs and cats have been diagnosed with diabetes 
in the United States and the prevalence of diabetes in dogs has doubled since 2007. 73,98 
Diabetes mellitus is a chronic disease requiring lifelong treatment and monitoring. Typical 
treatment involves the administration of twice daily insulin injections in addition to diet 
modification and frequent monitoring of blood glucose levels. Islet transplantation would 
offer a markedly improved treatment option for owners of diabetic pets.  
 
Widespread availability of this treatment will greatly depend on the accessibility of donor 
tissue from which to isolate islets. Pancreas obtained in local clinics where total cold 
ischemia times are limited to about 90 minutes can be successfully processed without 
internal preservation (i.e. vascular flushing) of the pancreas. However, potential donor 
pancreas may often come available in remote locations where transport times would be 
excessive and may include overnight shipping. Unfortunately, current pancreas 




require extensive flushing of the entire peritoneal vasculature in situ with high-priced 
preservation solutions. This practice is prohibitively complex and expensive to be feasible 
in veterinary medicine. Thus, we sought to develop a simplified “ex vivo” vascular flushing 
procedure specific to the canine pancreas with respect to the unique conditions 
associated with veterinary practice. Such a procedure would enable collection in remote 
sites and therefore increase the pool of available donor pancreas.  
 
Methods 
Pancreas Harvest and Perfusion 
The canine donor was administered at least 300 IU/kg heparin intravenously 10 minutes 
prior to euthanasia. Euthanasia solution (Euthasol® Virbac, Ft. Worth, TX) was then 
administered at 0.22 mL/kg intravenously. The abdominal cavity was exposed by gross 
resection of the ventral body surface. The pancreas was identified and positioned to 
clamp the portal vein, caudal vena cava, and splenic and pancreaticoduodenal vessels. 
The duodenum was double clamped and cut at the pylorus and at the distal edge of 
contact with the pancreas. The pancreas and duodenum were removed en bloc and 
placed on a sterile metal pan atop a frozen ice pack, and then the duodenum was 
resected and discarded. Clamps were removed and the vessels cannulated with a sterile 
20 g catheter. A modified HTK (histidine-tryptophan-ketoglutarate) preservation solution 
prepared with 5% (w/v) polyethylene glycol, M.W. 8000, was used to perfuse the 





The perfused pancreas was then immersed in povidone iodine solution for two minutes 
for surface decontamination, rinsed with sterile saline solution and placed in a sterile 
container filled with the modified HTK supplemented with gentamycin, a broad spectrum 
antibiotic, for overnight shipment. 
 
Pancreas Dissection and Digestion  
Upon receipt, the pancreas was immersed in povidone iodine solution for two minutes, 
rinsed thoroughly with saline solution, trimmed of excess non-pancreatic tissue, and then 
weighed on a sterile pan. The accessory pancreatic duct was located and the branch 
leading into the body/tail region of the pancreas was cannulated with a sterile catheter. 
Enzyme solution (Liberase® T-Flex, Roche Custom Biotech) in HBSS with added calcium 
and HEPES buffer was perfused into the ductal system until the gland was significantly 
distended with a target collagenase activity of 10 Wunsch Units and 0.6 mg of thermolysin 
per gram of pancreas digested. The head of the pancreas was neither perfused with 
enzyme nor included in further processing. Next, the distended pancreas was cut into 
several pieces and transferred to sterile flasks containing silicon nitride beads to aid in 
mechanical disruption. Regions not well preserved prior to cold storage were identified 
and discarded. Undigested tissue was weighed to determine the final mass of digested 
tissue. 
 
The flasks were filled with additional digestion buffer and clipped into a 38 ˚C shaking 
water bath at 120 rpm. Tissue dissociation and islet liberation were monitored by dithizone 




had been released from the extracellular matrix by adding cold media containing calf 
serum, which deactivated the enzyme. 
 
Islet Isolation and Purification 
The tissue digest was rinsed several times with fresh, cold RPMI cell culture medium with 
calf serum to remove remaining enzyme and cool the tissue. Islets were then purified from 
the digested tissue via density gradient centrifugation. Islets were suspended in a custom 
density gradient medium comprised of iodixanol and the modified HTK preservation 
solution adjusted to approximately 1.110 g/mL, and deposited beneath RPMI medium in 
50 mL centrifuge tubes to create a two-layer discontinuous gradient. Tubes were 
centrifuged and islets were collected from the supernatant. The majority of exocrine 
tissue, being denser than islets, migrated to the pellet and was discarded. 
 
Islet Yield and Purity Quantification 
Islet yield was calculated according to the standard method of conversion to islets 
equivalents, or “IEQ,” which accounts for the extreme size variation of native islets. 23 One 
IEQ is defined as a spherical islet with a diameter of 150 microns, which contains 
approximately 1000 individual islet cells. Essentially, IEQs are calculated by measuring 
the individual diameters of a representative aliquot of islets and applying standard 
conversion factors for each diameter range. Due to the size disparity of canine pancreas, 





Islet purity was evaluated by dithizone staining. Dithizone is a deep red-purple dye that 
strongly chelates zinc, which is highly concentrated in the beta cells of islets in association 
with insulin molecules. As such, islets stained with dithizone appeared bright red or purple 
(depending on incubation time, dithizone concentration, etc), whereas exocrine and 
ductal tissues were not stained. Five representative samples of the islet preparations 
were stained with dithizone and examined with a bright field microscope. The percent 
purity was estimated visually for each sample and averaged.  
 
Viability Assessment 
Islet viability was evaluated using a live/dead fluorescence assay that utilizes calcein AM 
and propidium iodide. Caclein AM itself is non-fluorescent, but, when taken up by living 
cells is modified such that it exhibits green fluorescence. Propidium iodide is a red 
fluorescent dye that is only able to enter dead cells and binds strongly to DNA. When 
bound to DNA, the fluorescence intensity of propidium iodide increases sharply, thus 
staining dead cells bright red. Islets stained with these dyes were imaged by fluorescence 
microscopy. The percentage of dead cells was calculated by taking the ratio of red pixels 
per islet to the total islet pixel area. Viability was expressed as the percentage of live cells. 
 
Glucose Stimulated Insulin Secretion Assessment 
Glucose stimulated insulin secretion was measured by incubating islets in media 
containing a range of glucose concentrations. The relative amount of insulin released by 
the islets into the surrounding medium was measured using Perkin Elmer alphaLISA 




baseline reading. Insulin assays were prepared and read immediately after glucose 
stimulation in the same wells following a novel all-in-one method developed in our 
laboratory. Four replicates were tested for each glucose concentration for each individual 
donor, averaged, and normalized to the baseline secretion signal, which was 2.8 mM 




“Ex vivo” vascular flushing for pancreas preservation 
Figure A1 displays photographs of two canine pancreas after preservation with the ex 
vivo vascular flushing method. The pancreas from donor 3 was well flushed and displayed 
thorough removal of blood as indicated by the pale-white appearance of the pancreas 
tissue throughout the majority of the organ. The pancreas from donor 4 is an example of 
incomplete vascular flushing, where large regions of the pancreatic tissue retained a pink 
color. However, the distal tail region of the pancreas from donor 4 was very well preserved 
(right side of image).  
 
Islet Isolation Outcomes 
Procurement variables and islet isolation outcomes for four separate canine pancreas are 
displayed in Table A1. Our method yielded an average of 49,560 IEQ per pancreas with 
a purity of 71%. Figure A2 shows representative color micrographs of dithizone stained 
islet immediately following islet isolation for all four donor pancreas. Islets appeared 




A2, islets from donor 3 were the least pure. Notably, this pancreas was exposed to the 
longest period of cold ischemia of the four pancreas included in this study at 20 hours.   
 
Islet Assessment 
Islet viability was evaluated using a live/dead fluorescent assay. Figure A3 shows a 
representative fluorescence micrograph of islets stained with calcein (green) and 
propidium iodide (red). A color micrograph of the same tissue co-stained with dithizone is 
included for reference to distinguish islet tissue from exocrine. Viability was quantified by 
determining the ratio of dead (red) pixels to the total number of pixels for individual islets, 
with a minimum of 25 islets evaluated per isolation. The average viability for the method 
was 94.8 +/- 2.8 % (N=3 isolations).   
 
Islet function was evaluated by glucose stimulated insulin secretion assay over a range 
of glucose conditions using an alphaLISA insulin assay to quantify insulin release. Figure 
A4 shows the average relative signal (N=4 isolations, tested in quadruplicate) at each 
glucose condition relative to a baseline reading of islets in prior to glucose stimulation. 
Islets generally secreted more insulin as glucose concentration increased, an indication 
of proper islet function.   
 
Discussion 
We have developed a technique that enables isolation of healthy canine islets under 
extreme conditions. To our knowledge, we are the first to report successful isolation of 




hours. Our method yielded on average 1487 islet equivalents (IEQ) per gram of 
digested tissue with a purity of 71%. Islets were approximately 95% viable and showed 
dose dependent glucose stimulated insulin secretion. By comparison, Vrabelova et al. 
reported an average yield of about 800 IEQ per gram from canine pancreas obtained 
post-circulatory death, and had  lower viability (~85%) but higher purity (~86%). 103 
Furthermore, their results were  obtained with only nominal cold storage time. Thus our 
method improves total islet yield and viability over current techniques, but even more 
advantageously, enables donor pancreas to be procured in remote locations and 
shipped to the processing center overnight.  
 
We found that our method produced encouraging results in comparison to more complex 
and expensive human organ preservation techniques. Kuhtreiber et al. conducted a study 
in 2010 on human pancreas processed after extended cold ischmia times, and reported 
an average yield of 4278 IEQ/gram of pancreas. 109 While our yields were considerably 
lower at 1487 IEQ/gram, the average cold ischemia time in our study was much higher at 
18.6 hours compared to 13.2 hours in the human study. Cold ischemia has been shown 
to have a profoundly negative impact on islet yield even when high quality vascular 
flushing and preservation is performed. 134   
 
Interestingly, we obtained a higher islet yield per gram when only the distal tail of the 
pancreas was processed (donor 4) vs. the entire tail and body. This corroborates previous 
histological studies that revealed a higher number and larger size of islets in the tail of the 




This is further confirmed by the results presented in this dissertation in chapter 3 that 
compared the effects of processing only the tail and body regions of the pancreas vs. the 
entire organ. Due to the high cost of tissue processing, particularly digestive enzymes 
and density gradient media, maximizing islet isolation efficiency will be critical in 
translating this treatment into the clinic.  
 
In conclusion, this study demonstrates a simple, cost effective method for canine 
pancreas preservation that enables the isolation of highly viable islets from pancreas 
procured under sub-optimal conditions in remote locations. Furthermore, our method 
tolerated extreme periods of cold ischemia, allowing the use of standard overnight 
shipping services rather than expensive custom express couriers. This method could 
therefore be employed to significantly increase the pool of potential donor pancreas 









Figure A1. Canine pancreas preservation.  
Shown here are photographs of pancreas preserved by our simplified “ex vivo” vascular flushing 
method. The pancreas from donor 3 (top image) was well flushed throughout the majority of the 
organ, indicated by the pale-while color of the pancreatic tissue. The pancreas from donor 4 
(bottom image) was flushed well only in the distal tail region shown in the right side of the image. 
The head and body of the pancreas, seen in the left side of the image, were poorly flushed with 
several regions still remaining pink in color as a result of blood remaining in the tissue. Poorly 
flushed regions are not viable after long periods of ischemia, and are therefore not processed 






Figure A2. Dithizone staining of isolated canine islets.  
Islet tissue from four separate canine pancreas immediately after isolation were stained with 
dithizone to evaluate islet quality and estimate purity. Islets from donor 3 contained a much 
higher percentage of non-islet tissue compared to the other isolations, as seen above. Islets all 






Figure A3. Islet viability.  
Islet preparations were evaluated using a live/dead fluorescence assay to determine the 
viability of islets isolated after extended cold ischemia. Shown above are islets stained with 
dithizone (left) and calcein/propidium iodide (right) for a representative sample of isolated 
canine islets. Dithizone was used for differentiation of islet and exocrine tissues. Calcein (green) 
fluorescence indicates live cells, where propidium iodide (red) fluorescence indicates dead 
cells. Completely non-fluorescent tissue is mostly acellular debris. Some tissues, while actually 
alive, fluoresce very dimly which is often due to poor penetration of the calcein dye through the 







Figure A4. Glucose stimulated insulin secretion.  
Isolated islets were incubated in various concentrations of glucose and secreted insulin was 
measured by alphaLISA insulin assay. Shown here are the average responses of islets from 
four separate isolations. Islets were tested in quadruplicate for each glucose condition for all 
islet isolations. Data are the alphaLISA signal intensity normalized to baseline intensity, which 
was obtained from islets in 2.8 mM glucose. Islets generally exhibited increased insulin 






Table A1. Islet isolation outcomes and procurement variables.  
Shown here are data for four islet isolations performed canine pancreas shipped to our 
laboratory overnight after vascular flushing with organ preservation solution. Yields are listed 
as total IEQ as well as IEQ per gram of digested pancreas to better account for the variability 
in size of the canine pancreas between donors. Only the distal tail region of the pancreas from 
donor 4 was processed due to incomplete flushing of the main body. For all other isolations, 
the body and tail of the pancreas were included. The head of the pancreas was not included in 






APPENDIX B: Developmental Studies Toward the Core-
shell Spherification Method (Chapter 5) 
 
Introduction 
This appendix is provided in support of Chapter 5 of the dissertation, which describes a 
novel method for producing cell-laden hydrogel microspheres, dubbed “core-shell 
spherification”. Several experiments are documented herein that were integral to the 
developmental of this new protocol, beginning with the initial proof of concept continuing 
through optimization for commercial deployment for islet transplantation. The current 
method was originally developed using a thiolated hyaluronic acid (HA) hydrogel system, 
sold commercially as “HyStem”, that was cross-linked via a Michael-type addition reaction 
between the thiol moieties and a polyethylene glycol diacrylate (PEGDA, MW ~3,400) 
cross-linker. This HA hydrogel was initially attractive from a commercial perspective as it 
had a well-established biocompatibility record and was already available in a cGMP 
compliant format. However, it became apparent over time that the method would 
potentially be compatible across a variety of hydrogel systems. For example, 
microspheres composed of PEG alone can also be fabricated from PEGDA polymers 







B1: Early Attempts and Proof of Concept 
B.1.1 PEG dimaleimide as a cross-linker for increased reaction kinetics  
The commercial version of this hydrogel includes a PEGDA cross-linker to initiate gel 
formation, and results in cross-linking times between 3-60 minutes depending on a 
number of variables including component concentrations and pH. However, in a 
discussion with the manufacturers of the product, it was learned that cross-linking times 
could be significantly reduced using a maleimide functionalized PEG in place of the 
standard acrylate. This was due to the greatly increased reactivity of maleimides toward 
the thiol groups on the HA polymers, which could reduce gelation time to a matter of 
seconds. The hypothesis was that with significantly increased reaction kinetics, the HA 
gel could be prepared as microspheres in a manner analogous to that of alginate, where 
droplets of the pre-polymer are simply extruded into a bath of cross-linker.    
 
PEG dimaleimide, (PEGDMal, MW 3,400 LaysanBio Inc., Arab, AL) was dissolved at 1% 
or 5% wt in PBS and adjusted pH 7.5. The HA precursor solution was added dropwise 
through a 27G needle into the stirred PEGDMal bath. Gelation of the HA was observed 
and occurred very rapidly. However, through several iterations of the experiment, all of 
the resulting gels were highly amorphous and possessed fiber-like protrusions dangling 
from the main gel structure. It was concluded that, despite the markedly increased cross-
linking kinetics, gelation was still too sluggish to produce uniform, spherical microspheres 





B1.2 Hybrid alginate/HA hydrogel microspheres 
Another approach was to combine the thiolated HA precursor with alginate in solution, 
utilizing the near instantaneous gelation of alginate to form the initial spherical construct 
while the HA polymers could be cross-linked slowly within the alginate matrix. Then after 
allowing sufficient time for the HA cross-linking to proceed, the alginate could be dissolved 
using by citrate chelation of the calcium ion cross-links.  
 
Initial sphere production using the hybrid solution of alginate and thiolated HA was 
successful. Also, in order to determine if the HA could even be successfully cross-linked 
under these conditions, spheres were produced with and without the PEGDA cross-linker. 
Spheres produced with the cross-linker did exhibit better initial stability as determined by 
comparing change in mass over time compared to uncross-linked hybrids. However, this 
strategy quickly proved to be ineffective, as all hybrid spheres began to degrade rapidly 
after 4 weeks. By comparison, spheres made with alginate alone exhibited relatively little 
degradation or change in mass over the same time period.  
 
B1.3 Emulsion based strategies for HA microencapsulation 
Emulsion-based strategies have been employed in the past for producing hydrogel 
microspheres, wherein an aqueous hydrogel precursor is rapidly stirred in a hydrophobic 
liquid, often mineral oil, to create small micro-droplets. 97,178 The micro-droplets are then 
cross-linked by various mechanisms and subsequently separated from the organic layer. 
This method was initially considered for islet microencapsulation in the thiolated HA gel, 




cytotoxicity to islets, which are notoriously vulnerable to mechanical shear, and do not 
replicate in vitro.  
 
B1.4 Proof of concept experiment for “core-shell spherification” method using 
thiolated HA hydrogel (HyStem) 
The following is an account of the initial proof of concept for the microencapsulation 
method described in Chapter 5 of this dissertation. The method was developed around 
the concept of liquid core alginate capsules, which have been used for purposes such as 
controlled release of drugs or proteins and cultivation of yeast or bacteria for biomolecule 
production, wherein the cells are trapped inside to facilitate easier collection of the target 
molecule. 208–212 The semi-permeable nature of these capsules gave rise to the notion 
that if small therapeutic molecules could diffuse out of the alginate shell, a small cross-
linking molecule should also be able to diffuse into it while a much larger hydrogel polymer 
remained trapped within.  
 
B1.4.1 Experimental summary   
A 1% (w/v) solution of the thiolated HA precursor was prepared with 25 mM calcium 
chloride, and added dropwise to a stirred bath containing 0.25% (w/v) low viscosity 
alginate (Protanal LF 10/60, FMC Biopolymer Inc.). Core-shell constructs formed 
immediately upon contact with the bath, and were stirred for 5 minutes and then 
transferred to PBS containing 10 mM calcium chloride for additional shell hardening. 
Images of the core-shell constructs containing the HA precursor are shown in figure 




possessed tail-like features. The core-shells were then transferred to a solution of 0.2% 
PEGDA dissolved in PBS, and incubated overnight.  
 
After overnight incubation, the core-shells were inspected microscopically. While the 
alginate shells appeared relatively unchanged, the cores contained what appeared to be 
hardened gel spheres that were markedly reduced in size, with clear separation between 
the gel core and the inner wall of the alginate shell (figure B1.1B). Constructs were then 
incubated in a 50 mM sodium citrate solution with gentle agitation for 45 minutes, 
collected in a wire screen, and rinsed well with fresh citrate solution. Alginate shells were 
visibly weakened after 20 minutes of incubation in citrate (figure B1.1C) and were 
completely dissolved upon the final rinsing step (figure B1.1D).  
 
B1.4.2 Discussion 
This proof of concept demonstrated the feasibility of using a core-shell approach to 
produce hydrogel microspheres under biologically compatible conditions. However, some 
challenges remained to be addressed. First, the overall size of the constructs was much 
too large for the intended application both in terms of delivery (i.e. injection) and nutrient 
diffusion. Unfortunately, current protocols for producing liquid-core capsules were limited 
to these large droplet sizes. Thus, miniaturization studies would need to be conducted. 
Second, the geometry of these constructs was not ideal, as many possessed tail-like 
protrusions. This would be undesirable in an any object indented for long-term in vivo 
residence as sharp or rough surfaces have been well established to be more 




questions of scale and sterility. These initial studies were carried out manually using a 
syringe and needle on an open benchtop. For this method to have any kind of clinical 
relevance for transplantation, it should be compatible with established bead production 
instrumentation designed for sterile operation.  
 
B2: Fluorescent Labelling of Hydrogel Polymer Core within Alginate Shell 
The core-shell spherification method is enabled by the ability of the alginate shell to 
prevent diffusion of the hydrogel precursor for a sufficient amount of time for cross-linking 
to occur. The results of the proof of concept experiment described in section B1.2 are 
evidence that this is largely the case, but it is still possible that some fraction of the HA 
polymers could diffuse out and potentially change the resulting properties of the gel 
microsphere from what would be expected given the initial precursor formulation. To 
investigate if, and to what extent, this occurs, the HA polymers were labelled with a 
fluorescent probe, prepared as core-shell constructs, and monitored via fluorescence 
microscopy.  
 
B2.1 Experimental Summary 
The thiolated HA was labelled with carboxyrhodamine 110-C5-maleimide, a green 
fluorescent probe (Biotium Inc., Fremont CA), which bonds to the HA via similar chemistry 
to the that of cross-linking reaction with PEGDMal. The HA precursor was incubated in 
the dark for 2 hours with the fluorescent probe at a concentration of 0.02 mg/mL, and then 
added dropwise into an alginate bath without the PEGDA cross-linker to form core-shell 




micrographs were taken after 2 and 72 hours to identify any loss of the HA precursor 
(figure B2.1). Two hours after formation of the core-shell constructs, a strong 
fluorescence signal was still observed in the core area of the construct. There also 
appeared to be some weak fluorescence emanating from within the alginate shell, 
suggesting some minor diffusion of the HA into the shell had occurred. At 72 hours, strong 
fluorescence was still seen in the core, and the alginate shell displayed negligible signal 
compared to the 2 hour observations.  
 
B2.2 Discussion 
The results of this experiment indicated that some diffusion of HA through the alginate 
shell probably occurs, but at an extremely low rate. Interestingly, loss of the HA polymer 
in the core area between 2 and 72 hours appeared minimal, yet the fluorescence 
originating from the alginate shell essentially disappeared during that time. This is most 
likely explained by autocross-linking of the HA polymers within the core area, which can 
occur in the presence of oxygen over the course of several hours as a result of disulfide 
bridge formation between the thiol groups. Thus, gelation likely occurred even in the 
absence of the more rapid cross-linking reaction with PEGDA, halting further loss of the 
HA polymers. 
 
The manufacturer of the thiolated HA reports the average molecular weight of the 
polymers to be in the range of 250 kDa. Thus, smaller hydrogel precursors would likely 
diffuse out more rapidly, thus shortening the available window for cross-linking and 




gel precursor can indeed escape the initial core-shell construct, the loss appears to be 
very minimal and likely has very little impact on the resulting gel structures produced with 
this particular material.  
 
B3: Optimization for Microscale Production of Core-Shell Constructs 
The following section describes the challenges encountered in reducing the size of the 
hydrogel spheres to within a range suitable for cell transplantation. In light of this 
objective, a Buchi B-395 Pro micro-droplet generation system was incorporated. The 
Buchi B-395 Pro was selected as it was specifically designed for sterile operation and cell 
encapsulation, and is cGMP ready.  
 
B3.1 Early experiences with microscale core-shell spherification 
Initial attempts at reducing the size core-shell constructs to the microscale (i.e. below 1 
mm) were met with significant challenges. The dramatic reduction in droplet mass and 
volume was perhaps the most impactful factor. For example, a spherical 2.5 mm droplet 
corresponds to volume of approximately 8.2 microliters, whereas a 0.5 mm droplet is only 
0.065 microliters, a 125-fold decrease. Notably, this also meant the total free calcium, 
necessary for forming the alginate shell, was reduced by the same factor. Due to these 
factors, early trials at making sub-millimeter particles produced extremely weak and 






B3.2 Calcium concentration 
Eventually, increasing the calcium concentration to at least 100 mM was found to be an 
effective strategy to improve the strength of the alginate shells at the microscale. For 
particularly small constructs (e.g. < 500 microns), concentrations near 200 mM were 
necessary to form sufficiently strong shells. Because these elevated calcium levels were 
later determined to be cytotoxic to islets (chapter 5), efforts were focused on slightly larger 
spheres between 600-1000 microns produced with 100 mM calcium in the hydrogel 
precursor solution.  
 
B3.3 Alginate concentration and viscosity differential 
A common issue aside from the strength of the alginate shell was the construct 
morphology. As depicted in figure B3.1, cores often had grossly non-spherical geometry, 
were teardrop shaped, or possessed appendage-like deformities. These issues were 
determined to be heavily correlated to the viscosity differential between the droplets and 
the alginate bath, which was several times that of water (~ 5-6 cSt) for formulations being 
examined at the time (0.25%-0.5% low viscosity alginate). Further experimentation 
revealed an alginate bath concentration of 0.12 – 0.15% to be a suitable balance between 
ensuring alginate shell stability and reducing bath viscosity, which for that range was 
approximately 2.5 -3.5 cSt, as measured by a glass capillary viscometer. At this alginate 
level, a droplet viscosity of approximately 60 cSt or higher consistently resulted in high 
quality, sub-millimeter core-shell constructs. Sample images of the optimized core-shell 





B3.4 Hydrogel precursor solution density 
Another consideration for micro-scale production of core-shell constructs was the density 
of the hydrogel precursor solution. Increased droplet density (~1.05 -1.08 g/mL) was 
found to improve overall quality of the resulting constructs, particularly for smaller droplet 
sizes, by preventing the droplets from clinging to the surface of the bath. At lower density, 
small, thin, tail-like features often formed as the droplets sank slowly into the alginate bath 
(figure B3.2). Increasing the density of the core solution was also of great value for cell 
encapsulation, as the cells were more neutrally buoyant in the denser solutions, mitigating 
settling of the tissue during microsphere production.  
 
B4: Precursor Solution Formulation Development for PEG Microspheres 
As discussed in the preceding section, a minimum droplet viscosity was necessary to 
ensure high quality core-shell constructs and resulting microspheres. When producing 
PEG microspheres using only PEGDA (described in chapter 5), fairly high concentrations 
of polymer were needed to meet the viscosity requirement due to the relatively small 
molecular weight of these polymers. A well-known property of PEGDA gels is the 
propensity to swell with water after fabrication, and the extent of this swelling is correlated 
to the polymer concentration and polymer molecular weight. 213–216 However, there was 
very little published data on the effect of combining PEGDA polymers of different 
molecular weights on swelling behavior. Thus, a study was conducted to identify a 
PEGDA formulation that would both meet the viscosity requirements for core-shell 
spherification and also exhibit the least amount of swelling in order to keep microsphere 




B4.1 Experimental Summary 
Several different ratios of PEGDA 3.4 kDa and PEGDA 20 kDa were compared to gels 
made with PEGDA 10 kDa alone at the same polymer concentration. Cylindrical gels were 
made using a custom mold at a 30% total PEGDA mass fraction and contained 0.1% 
(w/w) Irgacure 2959 as a photoinitiator. Gels were weighed immediately after fabrication 
and again after 24 hours once equilibrium swelling was reached. Swollen gels were dried 
on a Kimwipe to remove excess water from the surface of the gel. The results of this 
experiment are summarized in table B4.1. The amount of swelling observed in the 10 
kDa gels was higher than any of the hybrid formulations tested. This was unexpected 
given the theoretical average molecular weights of the hybrid gels, which were higher in 
than 10 kDa for 3 of the 5 formulations.  
 
B4.2 Discussion 
The goal of this study was to identify a formulation of PEGDA gel precursor that would 
both meet the minimum viscosity requirement while exhibiting the least amount of 
swelling. Swelling was undesirable as it increased the size of the resulting microspheres, 
limiting their convenience and potentially leading to problems with nutrient diffusion. 
Based on these results, the 18/12% hybrid formulation was chosen as the optimal core 
solution due to its viscosity just meeting the target of about 60 cSt and exhibiting a much 
lower swelling ratio than the 10 kDa formulation, which was also about 60 cSt. While the 
20/10% gel exhibited even less swelling than the 18/12% gels, the viscosity of this solution 





B5: Development of UV Photo-cross-linking Protocol for PEG Microspheres 
A protocol for cell encapsulation in PEG microspheres using PEGDA was desirable due 
to its long-standing biocompatibility record, wide commercial availability and tight 
production control. 213–217 However, the relatively small molecular weight of the PEGDA 
polymers presented a challenge when incorporated into the core-shell spherification 
method, as the alginate shells were too porous to contain these polymers for extended 
periods of time. As such, increasing the gelation rate of these gels was critical to retain 
sufficient concentration of the polymer to form quality microspheres, and is generally 
achieved in one of two ways, 1) increase UV light intensity (i.e. irradiance, or watts/area) 
or 2) increase photoinitiator concentration.  
 
Initial trials were conducted using a standard laboratory grade 6W long-wave UV lamp 
(UVL-56, UVP, LLC.), which was sufficient to cross-link PEGDA gels on the benchtop in 
5-15 minutes, and had an irradiance rated at 1.35 mW/cm2 at a distance of 3 inches 
according to the manufacturer. However, when used for core-shell spherification, no 
cross-linking was observed under any conditions with this lamp. The next iteration of the 
protocol utilized a much higher power 100W lamp (Blak-Ray B-100AP, UVP, LLC) with 
an irradiance of 21.7 mW/cm2 at a distance of 2 inches. Cross-linking times using this 
lamp were rapid enough to produce PEG microspheres, but at the levels of photoinitiator 
required (0.2%), resulted in excessive cytotoxicity. When photoinitiator concentration was 
reduced into non-cytotoxic ranges (<0.08%), the resulting microspheres were extremely 
weak, easily damaged, and swelled markedly such that encapsulated islets often fell out 




Because an increase in photoinitiator concentration was not an option due to cytotoxicity, 
another escalation in UV lamp power was the only apparent alternative. Excellent results 
were finally achieved with a 400W lamp with an irradiance rating of 200 mW/cm2 at a 
distance of 3 inches (PortaRay 400, Uvitron International, Inc.). The full irradiance of 200 
mw/cm2 was found to be unnecessarily high, as gels could be fully cross-linked in under 
30 seconds at approximately 40 mw/cm2 using extremely low photoinitiator 
concentrations (0.025%). Another advantage of this lamp was its much wider coverage 
area, resulting in more complete and even irradiance of the cross-linking bath during core-
shell spherification.  
 
B6: Evaluation of Bead Generation Technologies for Application Specific Process 
Optimization  
The Buchi B-395 Pro micro-droplet generator is compatible with two different nozzle 
systems for producing liquid droplets, a vibrational nozzle and an air jet nozzle. The 
vibrational nozzle system produces droplets via vibrational frequency applied to the 
nozzle head to disrupt a laminar fluid stream. The size of the resulting droplets is 
controlled by the nozzle size, fluid flow rate, and vibrational frequency, where smaller 
nozzles, reduced fluid flow, and higher frequencies produce smaller droplets. The air jet 
nozzle utilizes an internal fluid nozzle within a larger concentric nozzle for a compressed 
gas, namely air or nitrogen, which creates a cylindrical jacket of airflow around the central 
nozzle. As the fluid is pumped through the central nozzle, droplets are blown off by the 
airflow. In this system, droplet size is strongly correlated to the airflow rate, and also to 




B6.1 Experimental Summary  
These droplet generation technologies were investigated for microencapsulation of islets 
using the core-shell spherification method. Microspheres were produced using both 
systems with and without islets. Islets above 200 microns in diameter were removed using 
a steel mesh prior to encapsulation to avoid clogs. Then, the size distribution of the 
resulting spheres was analyzed by measuring the diameters of 100 individual spheres 
from a representative sample of each group, which are displayed in figure B6.1. Because 
the nozzles for the two systems were different sizes, data were normalized to the average 
bead size of the empty spheres within each group for better comparison of the effects of 
the different nozzle systems on the microsphere size distribution. Interestingly, a marked 
relative increase in microsphere diameter and heterogeneity was observed with the 
vibrational nozzle system when islets were included. This trend was not seen with the air 
jet nozzle. In fact, the introduction of islets appeared to improve size uniformity in the air 
nozzle group, as fewer outliers per 100 spheres were observed compared to empty 
spheres. However, the average diameter did not appear to differ significantly from the 
empty spheres in this group.   
 
B6.2 Discussion 
The vibrational nozzle system was found to be better for fabricating empty spheres, 
generating the most uniform size distribution of microspheres. However, the air jet nozzle 
was vastly superior to the vibrational nozzle for encapsulating islets. Microsphere size 
distribution was extremely heterogeneous when using the vibrational nozzle with islets. A 




principle of laminar fluid flow as does the vibrational nozzle. The inclusion of the relatively 
large islet particles may have disrupted the laminar flow required for proper droplet 
generation with the vibrational nozzle. In contrast, size uniformity appeared to improve 
with the inclusion of islets using the air nozzle compared to empty spheres, though the 
reason for this is unclear. Thus, the air nozzle system was selected for future development 
in islet encapsulation, while the vibrational nozzle may be preferred for encapsulation of 
proteins, or smaller, single cells. 
 
General Summary 
The fundamental concept of the core-shell spherification method is relatively simple; a 
temporary, spherical alginate shell holds a desired hydrogel precursor in place long 
enough for it to cross-linking, and is subsequently dissolved. However, in practice, several 
variables came to light that required further investigation, particularly with regard to 
miniaturization of the initial proof of concept to the target microsphere size of < 1mm in 
diameter. The dynamic environment inherent to this method presented additional 
challenges when utilizing the photo-cross-linkable PEGDA gel precursor, which diffused 
out of the alginate shell much more rapidly on account of its low molecular weight 
compared to the HA polymers. To overcome this, the cross-linking rate had to be 
significantly increased, but in such a way that cytotoxicity to encapsulated cells was 
avoided. Ultimately, it was determined that a markedly increased irradiance intensity was 
necessary to achieve sufficient cross-linking kinetics without increasing photoinitiator 
concentrations to toxic levels. Furthermore, because a minimal core solution viscosity is 




formulation of PEGDA precursor what would meet the viscosity requirement while 
resulting in the least extensive post-fabrication swelling behavior. Finally, droplet 
generation technology was also evaluated to elucidate the benefits and limitations of two 
available nozzle systems. An air jet nozzle system had clear benefit for encapsulation of 
large cellular aggregates, i.e. islets, while a vibrational nozzle facilitated excellent control 
of microsphere diameter when islets were not present, indicating that this nozzle system 











Figure B1.1. Core-shell spherification proof of concept study. 
Shown here are photomicrographs taken of the initial proof of concept study for the core-shell 
spherification method. Core-shell constructs containing the HA precursor trapped within an 
alginate shell (A). Core-shell constructs after overnight cross-linking (B). Weakened alginate 
shells after 20 minutes of incubation in 50 mM citrate (C). Final HA spheres after complete 
alginate shell dissolution (D). Scale bars = 2 mm.  





Figure B2.1. Fluorescent labelling of HA precursor. 
HA prepolymers were labelled with a green fluorescent probe in order to investigate the 
effectiveness of the alginate shell for preventing diffusion of the HA out of the core area. 
Fluorescent images of the core-shell constructs produced with the labelled HA were taken after 






Figure B3.1. Poorly formed core-shell constructs. 
Initial attempts to reduce the size of the core-shell constructs were largely unsuccessful. 
Constructs had very poor sphericity, rough edges, and large protrusions. In many cases, 
alginate shells were too weak to withstand even mild stirring or handling, and would collapse 
onto themselves. A collapsed core-shell can be seen in the bottom right corner of the figure. 







Figure B3.2. Examples of tail-like features in early microspheres. 
Smaller, lighter droplets often appeared to linger near the surface of the alginate bath upon 
contact, resulting in the formation of small, tail-like features extending from an otherwise 
spherical construct. Increasing the density of the droplet solutions, among other modifications, 








Figure B5.1. Results of insufficient cross-linking rate. 
Islet microspheres seen above were fabricated with insufficient UV light intensity and were thus 
very weak and easily damaged. Empty void spaces can be seen where islets were too loosely 







Figure B6.1. Comparison of droplet generation nozzle systems. 
Empty and islet containing microspheres were fabricated using two different droplet generation 
systems. The diameters of 100 individual microspheres produced by either a vibrational nozzle 
(left) or air jet nozzle (right) were measured, and then normalized to the average diameter of 







Table B4.1. PEGDA swelling study results. 
Hybrid gel precursor was made by combining PEGDA 3.4 kDa and 20 kDa at various ratios. 
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